var title_f1_24_1408="Bipolar radiofrequency ablation";
var content_f1_24_1408=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F81118&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F81118&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bipolar radiofrequency endometrial ablation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 422px; height: 242px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Novaure endometrial ablation system",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_24_1408=[""].join("\n");
var outline_f1_24_1408=null;
var title_f1_24_1409="Patient information: Trigeminal neuralgia (The Basics)";
var content_f1_24_1409=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Trigeminal neuralgia (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/trigeminal-neuralgia-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H10751153\">",
"      <span class=\"h1\">",
"       What is trigeminal neuralgia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Trigeminal neuralgia (TN) is a condition that causes sudden and severe pain in parts of the face.",
"     </p>",
"     <p>",
"      TN is caused by a problem with the trigeminal nerve, which is a nerve that runs from the brain to the face.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10751168\">",
"      <span class=\"h1\">",
"       What are the symptoms of trigeminal neuralgia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;TN causes sharp and stabbing pain in the cheek, lower face, or around the eye. The pain lasts a few seconds to a few minutes, and usually happens on only 1 side of the face. TN can also cause muscle spasms in the face that happen at the same time as the pain. Most people with TN have repeated episodes of pain.",
"     </p>",
"     <p>",
"      Often, certain movements or activities make the pain attacks happen. These can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Touching the face",
"       </li>",
"       <li>",
"        Chewing",
"       </li>",
"       <li>",
"        Talking",
"       </li>",
"       <li>",
"        Brushing the teeth",
"       </li>",
"       <li>",
"        Smiling",
"       </li>",
"       <li>",
"        Cold air on the face",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10751182\">",
"      <span class=\"h1\">",
"       Will I need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Maybe. Your doctor or nurse should be able to tell if you have TN by learning about your symptoms and doing an exam.",
"     </p>",
"     <p>",
"      He or she might do tests to get more information about your TN or what&rsquo;s causing it. These tests can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        An MRI or CT scan of your brain &ndash; These are imaging tests that can create pictures of your brain",
"       </li>",
"       <li>",
"        Tests to check how the nerves and muscles in your face are working",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10751197\">",
"      <span class=\"h1\">",
"       How is trigeminal neuralgia treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;TN is usually treated with medicine. Doctors can use different types of medicines to treat TN. Most often doctors prescribe a type of medicine normally used to prevent seizures, called antiepileptics. These medicines quiet the nerve signals that cause pain in TN.",
"     </p>",
"     <p>",
"      For most people, the medicine helps reduce the number of TN attacks they have and makes their pain less severe. But if medicines don&rsquo;t help enough or cause too many side effects, your doctor might talk with you about other treatment options. These include different types of procedures that quiet the nerve and make it less likely to fire. These surgical treatments might help with symptoms, but they are invasive and can also make the face numb.",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?1/24/1409?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16844 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.131.240.2-31C67D9254-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_24_1409=[""].join("\n");
var outline_f1_24_1409=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10751153\">",
"      What is trigeminal neuralgia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10751168\">",
"      What are the symptoms of trigeminal neuralgia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10751182\">",
"      Will I need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10751197\">",
"      How is trigeminal neuralgia treated?",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_24_1410="Atypical lymphocytes";
var content_f1_24_1410=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F55986&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F55986&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Atypical lymphocytes in infectious mononucleosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 417px; height: 266px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Peripheral smear from a patient with infectious mononucleosis shows three atypical lymphocytes with generous cytoplasm.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carola von Kapff, SH (ASCP).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_24_1410=[""].join("\n");
var outline_f1_24_1410=null;
var title_f1_24_1411="Patient information: Time to stop driving? (The Basics)";
var content_f1_24_1411=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?31/14/31970\">",
"         Patient information: Dementia (including Alzheimer disease) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?42/40/43650\">",
"         Patient information: Epilepsy in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?31/3/31793\">",
"         Patient information: Evaluating memory and thinking problems (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?37/60/38850\">",
"         Patient information: Implantable cardioverter-defibrillators (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?2/20/2370\">",
"         Patient information: Mild cognitive impairment (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?27/19/27953\">",
"         Patient information: Narcolepsy (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?23/55/24435\">",
"         Patient information: Stroke (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?36/5/36946\">",
"         Patient information: Syncope (fainting) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?31/22/32098\">",
"         Patient information: Tips for caregivers of people with Alzheimer disease (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?14/37/14934\">",
"         Patient information: Dementia (including Alzheimer disease) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?11/20/11589\">",
"         Patient information: Implantable cardioverter-defibrillators (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?33/27/34229\">",
"         Patient information: Seizures in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?4/9/4245\">",
"         Patient information: Syncope (fainting) (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Time to stop driving? (The Basics)",
"    </div>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H880534588\">",
"      <span class=\"h1\">",
"       Is there a set age when people should stop driving?",
"      </span>",
"      &nbsp;&mdash;&nbsp;No. There is no set age when older people should stop driving. It depends on many factors. It is true that older drivers can still be safe drivers. But it is also true that, besides teens, older drivers are involved in more deadly car crashes than any other age group.",
"     </p>",
"     <p>",
"      Being able to drive is important to older people, and most people don&rsquo;t want to give it up. Driving gives people the freedom to go where they want, when they want. When people can&rsquo;t or don&rsquo;t drive, they have to depend on others. This can be hard for many reasons.",
"     </p>",
"     <p>",
"      Each state has its own rules about older drivers. In some states, older drivers need to take written, vision, or road tests every time they renew their license. In other states, older drivers take no tests, or only a vision test, when they renew their license.",
"     </p>",
"     <p>",
"      One way to check if someone is a safe driver is to have him or her take an on-the-road driving test. This test can be set up through your state or sometimes through a program that specifically works with older adults.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H880534603\">",
"      <span class=\"h1\">",
"       How do doctors decide if a person should stop driving?",
"      </span>",
"      &nbsp;&mdash;&nbsp;To help decide if a person should stop driving, the doctor will:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Talk with the person &ndash; He or she will ask about the person&rsquo;s medical conditions. Certain medical conditions make it more unsafe for people to drive. Some of these include heart problems, movement disorders, diabetes, arthritis, and sleep disorders. The doctor will also ask about medicines the person takes. Certain medicines can make people feel sleepy or slow down their reflexes.",
"       </li>",
"       <li>",
"        Do an exam &ndash; As part of the exam, the doctor will see how well the person moves, especially his or her neck, shoulders, and wrists. He or she will check the person&rsquo;s balance and grip strength. The doctor will also check the person&rsquo;s vision and hearing. Problems with any of these things can affect a person&rsquo;s driving.",
"       </li>",
"       <li>",
"        Check the person&rsquo;s thinking and memory &ndash; The doctor will ask questions to check the person&rsquo;s thinking and memory. It is unsafe for people with serious thinking or memory problems to drive.",
"       </li>",
"       <li>",
"        Talk with family members &ndash; The doctor will ask the family about the person&rsquo;s driving. He or she will want to know if the person has gotten lost when driving on a familiar route or had any near-accidents.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      In some states, doctors need to report people who can no longer drive safely.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H880534618\">",
"      <span class=\"h1\">",
"       What conditions can keep people from driving short-term?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Certain things can keep people from driving for a short period of time. They include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        A heart attack &ndash; This is when 1 of the arteries that bring blood to the heart gets blocked.",
"       </li>",
"       <li>",
"        Fainting",
"       </li>",
"       <li>",
"        A stroke &ndash; A stroke happens when there is no blood flow to part of the brain. This damages the nervous system and can cause problems with thinking, speaking, and moving an arm or leg.",
"       </li>",
"       <li>",
"        A seizure &ndash; Seizures are waves of abnormal electrical activity in the brain. They can make people pass out, or move or behave strangely.",
"       </li>",
"       <li>",
"        Getting a device called an &ldquo;implantable cardioverter-defibrillator&rdquo; &ndash; This device prevents sudden death from a heart rhythm problem.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      The rules are different for each state. But in general, after these things happen, people need to wait a certain amount of time before they can drive again. For example, people who have a seizure need to be seizure-free for a certain amount of time before they can drive again. In some cases, people might need their doctor&rsquo;s permission before they drive again.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H880534633\">",
"      <span class=\"h1\">",
"       What if my family member should stop driving, but won&rsquo;t?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If your family member should stop driving but won&rsquo;t, you can try these tips. You can:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Hide the car keys.",
"       </li>",
"       <li>",
"        Take the battery out of the car so it won&rsquo;t start.",
"       </li>",
"       <li>",
"        Park the car on another block or in a spot where your family member won&rsquo;t find it.",
"       </li>",
"       <li>",
"        Make plans for someone else to do the driving.",
"       </li>",
"       <li>",
"        Ask the doctor to write a prescription saying the person should not drive.",
"       </li>",
"       <li>",
"        Set up a driving test with the state.",
"       </li>",
"       <li>",
"        Work with a social worker to get help with the situation.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If the person&rsquo;s license has been taken away, and he or she keeps driving, it can lead to problems. For example, if your family member gets into an accident, he or she will have to pay for damages and might get in trouble with the law.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H880534648\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?37/60/38850?source=see_link\">",
"       Patient information: Implantable cardioverter-defibrillators (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?36/5/36946?source=see_link\">",
"       Patient information: Syncope (fainting) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?31/14/31970?source=see_link\">",
"       Patient information: Dementia (including Alzheimer disease) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?2/20/2370?source=see_link\">",
"       Patient information: Mild cognitive impairment (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?31/22/32098?source=see_link\">",
"       Patient information: Tips for caregivers of people with Alzheimer disease (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?31/3/31793?source=see_link\">",
"       Patient information: Evaluating memory and thinking problems (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/55/24435?source=see_link\">",
"       Patient information: Stroke (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?42/40/43650?source=see_link\">",
"       Patient information: Epilepsy in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/19/27953?source=see_link\">",
"       Patient information: Narcolepsy (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?33/27/34229?source=see_link\">",
"       Patient information: Seizures in adults (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?4/9/4245?source=see_link\">",
"       Patient information: Syncope (fainting) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?14/37/14934?source=see_link\">",
"       Patient information: Dementia (including Alzheimer disease) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?11/20/11589?source=see_link\">",
"       Patient information: Implantable cardioverter-defibrillators (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 14, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?1/24/1411?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16622 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-79.122.249.114-555B9DE994-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_24_1411=[""].join("\n");
var outline_f1_24_1411=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H880534588\">",
"      Is there a set age when people should stop driving?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H880534603\">",
"      How do doctors decide if a person should stop driving?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H880534618\">",
"      What conditions can keep people from driving short-term?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H880534633\">",
"      What if my family member should stop driving, but won&rsquo;t?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H880534648\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/37/14934?source=related_link\">",
"      Patient information: Dementia (including Alzheimer disease) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?31/14/31970?source=related_link\">",
"      Patient information: Dementia (including Alzheimer disease) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?42/40/43650?source=related_link\">",
"      Patient information: Epilepsy in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?31/3/31793?source=related_link\">",
"      Patient information: Evaluating memory and thinking problems (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?11/20/11589?source=related_link\">",
"      Patient information: Implantable cardioverter-defibrillators (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/60/38850?source=related_link\">",
"      Patient information: Implantable cardioverter-defibrillators (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?2/20/2370?source=related_link\">",
"      Patient information: Mild cognitive impairment (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/19/27953?source=related_link\">",
"      Patient information: Narcolepsy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/27/34229?source=related_link\">",
"      Patient information: Seizures in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/55/24435?source=related_link\">",
"      Patient information: Stroke (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?4/9/4245?source=related_link\">",
"      Patient information: Syncope (fainting) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/5/36946?source=related_link\">",
"      Patient information: Syncope (fainting) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?31/22/32098?source=related_link\">",
"      Patient information: Tips for caregivers of people with Alzheimer disease (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_24_1412="Lymphomatoid papulosis 3";
var content_f1_24_1412=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F54022&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F54022&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Lymphomatoid papulosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lymphomatoid papulosis nodule with central ulceration.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_24_1412=[""].join("\n");
var outline_f1_24_1412=null;
var title_f1_24_1413="Rat bite fever";
var content_f1_24_1413=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Rat bite fever",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/24/1413/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/24/1413/contributors\">",
"     Michele Trucksis, PhD, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/24/1413/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/24/1413/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/24/1413/contributors\">",
"     Morven S Edwards, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/24/1413/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/24/1413/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/24/1413/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 6, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rat-bite fever (RBF) (also known as Haverhill fever) is a rarely diagnosed, systemic illness caused by infection with either Streptobacillus moniliformis or Spirillum minus. S. moniliformis causes most cases of the disease in the United States; S. minus causes RBF primarily in Asia, although it probably is present worldwide.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;S. moniliformis is commonly found in the nasal and oropharyngeal flora of rats and probably other rodents. The rate of nasopharyngeal carriage of S. moniliformis by healthy laboratory rats has been reported to vary between 10 and 100 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?1/24/1413/abstract/1\">",
"     1",
"    </a>",
"    ]. Human infection can result from a bite or scratch from an infected or colonized rat, handling of an infected rat, or ingestion of food or water contaminated with infected rat feces [",
"    <a class=\"abstract\" href=\"UTD.htm?1/24/1413/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Contamination of food and water with S. moniliformis has caused several outbreaks of RBF [",
"    <a class=\"abstract\" href=\"UTD.htm?1/24/1413/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. In 1926, 86 persons in Haverhill, Massachusetts, developed a febrile illness (Haverhill fever) following the consumption of contaminated unpasteurized milk [",
"    <a class=\"abstract\" href=\"UTD.htm?1/24/1413/abstract/3\">",
"     3",
"    </a>",
"    ]. In 1983 an outbreak involving 304 boarding school children occurred in Chelmsford, England caused by water contaminated with rat excretions [",
"    <a class=\"abstract\" href=\"UTD.htm?1/24/1413/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Approximately 30 percent of patients with RBF do not report having been bitten or scratched by a rat [",
"    <a class=\"abstract\" href=\"UTD.htm?1/24/1413/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Risk factors for RBF include handling rats at home and in the workplace (eg, laboratories or pet stores).",
"   </p>",
"   <p>",
"    RBF is rare in the United States, with only a few cases documented each year. However, because RBF is not a nationally notifiable disease, and it is likely to respond to empiric antibiotic therapy without diagnosis, its actual incidence is not known.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;S. moniliformis and S. minus are pleomorphic fastidious branching Gram negative bacilli (",
"    <a class=\"graphic graphic_picture graphicRef53591 \" href=\"UTD.htm?24/24/24960\">",
"     picture 1",
"    </a>",
"    ). They stain irregularly and can be mistaken for Gram positive pleomorphic rods. The bacteria are aerobic, facultatively anaerobic, and require specific media for isolation (10 to 20 percent serum) and incubation in a 5 to 10 percent CO2 environment.",
"   </p>",
"   <p>",
"    S. moniliformis grows slowly. As a result, cultures should be held for at least five days to allow identification. On solid agar plates, pinpoint colonies representing cell wall-defective variants (L-forms) may surround larger gray-white colonies [",
"    <a class=\"abstract\" href=\"UTD.htm?1/24/1413/abstract/7\">",
"     7",
"    </a>",
"    ]. Inoculation into thioglycolate broth enriched with serum produces growth in typical \"puff-ball\" colonies [",
"    <a class=\"abstract\" href=\"UTD.htm?1/24/1413/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    S. moniliformis can be identified by a characteristic fatty acid profile on gas chromatography [",
"    <a class=\"abstract\" href=\"UTD.htm?1/24/1413/abstract/8\">",
"     8",
"    </a>",
"    ]. In contrast, biochemical testing is often difficult and results are inaccurate because of the fastidious nature of the organism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The symptoms of RBF caused by S. moniliformis start abruptly two to ten days following exposure with fever, myalgias, arthralgias, vomiting, and headache. The fever is often irregularly relapsing. The initial symptoms are followed by a maculopapular rash on the extremities [",
"    <a class=\"abstract\" href=\"UTD.htm?1/24/1413/abstract/9\">",
"     9",
"    </a>",
"    ], followed by polyarthritis in up to 50 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?1/24/1413/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The rash is typically seen on the extensor surface of the extremities and may involve the palms and soles [",
"    <a class=\"abstract\" href=\"UTD.htm?1/24/1413/abstract/12\">",
"     12",
"    </a>",
"    ]. Although usually maculopapular, it can be petechial, purpuric, or pustular.",
"   </p>",
"   <p>",
"    In contrast, RBF caused by S. minus has a longer incubation period (one to three weeks), and the initial wound may reappear at the onset of the systemic illness or persist with edema and ulceration. Arthritis is not a common clinical finding.",
"   </p>",
"   <p>",
"    The infection can be rapidly fatal both in children and adults [",
"    <a class=\"abstract\" href=\"UTD.htm?1/24/1413/abstract/2,13,14\">",
"     2,13,14",
"    </a>",
"    ]. Two cases of fulminant sepsis and death in previously healthy adults occurred in the United States in 2003, one following a rat bite in a pet store and the other most likely from a sick pet rat [",
"    <a class=\"abstract\" href=\"UTD.htm?1/24/1413/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The complications reported in the Chelmsford and Haverhill outbreaks included:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chelmsford &mdash; Four patients with moderately severe symptoms had bacteremia [",
"      <a class=\"abstract\" href=\"UTD.htm?1/24/1413/abstract/15\">",
"       15",
"      </a>",
"      ]. No further complications were noted.",
"     </li>",
"     <li>",
"      Haverhill &mdash; Eleven of 17 patients tested had positive blood cultures; two patients developed pneumonia [",
"      <a class=\"abstract\" href=\"UTD.htm?1/24/1413/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most of the serious invasive infections have appeared as case reports and include meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/24/1413/abstract/14\">",
"     14",
"    </a>",
"    ], endocarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/24/1413/abstract/16,17\">",
"     16,17",
"    </a>",
"    ], including prosthetic valve endocarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/24/1413/abstract/18\">",
"     18",
"    </a>",
"    ], myocarditis, pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?1/24/1413/abstract/13\">",
"     13",
"    </a>",
"    ], focal abscesses [",
"    <a class=\"abstract\" href=\"UTD.htm?1/24/1413/abstract/7\">",
"     7",
"    </a>",
"    ], bacteremia, septic arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/24/1413/abstract/19,20\">",
"     19,20",
"    </a>",
"    ], and multiple organ failure [",
"    <a class=\"abstract\" href=\"UTD.htm?1/24/1413/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians should consider RBF in the differential diagnosis of an unexplained febrile illness or sepsis in patients reporting rat exposure especially if the fever pattern is relapsing or intermittent, a maculopapular rash is present,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the patient has asymmetrical polyarthritis.",
"   </p>",
"   <p>",
"    Blood or synovial fluid collected in tubes without sodium polyanethol sulfonate, an anticoagulant that can inhibit growth of the organism, should be submitted for culture. The microbiology laboratory should be alerted to the suspicion of RBF so that specific media and culture conditions are used to optimize isolation of the organism. In addition, the laboratory should incubate the blood cultures for 21 days. No serologic test is available.",
"   </p>",
"   <p>",
"    Molecular techniques, such as polymerase chain reaction (PCR), have been developed to assist in the diagnosis of RBF. While not clinically available to most practitioners, these techniques show considerable promise for a quick, accurate diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/24/1413/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The case-fatality rate is as high as 25 percent in untreated patients [",
"    <a class=\"abstract\" href=\"UTD.htm?1/24/1413/abstract/1,22-25\">",
"     1,22-25",
"    </a>",
"    ]. Treatment of RBF associated with an animal bite should begin with appropriate management of the bite wound. Such management includes copious irrigation of wounds and determination of the need for tetanus or rabies postexposure prophylaxis.",
"   </p>",
"   <p>",
"    Rats and other small rodents are almost never infected with rabies, and there has",
"    <strong>",
"     never",
"    </strong>",
"    been a case of transmission to a human from one of these animals. If the animal is not available for testing, postexposure prophylaxis for bites should be considered individually in consultation with the public health authorities. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/24/28038?source=see_link&amp;anchor=H6#H6\">",
"     \"Soft tissue infections due to dog and cat bites\", section on 'Wound management'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/21/2393?source=see_link&amp;anchor=H13#H13\">",
"     \"Rabies immune globulin and vaccine\", section on 'Postexposure prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In vitro, S. moniliformis is usually sensitive to penicillin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35735?source=see_link\">",
"     cefotaxime",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    ; and resistant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/20/17733?source=see_link\">",
"     polymyxin B",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/35/34352?source=see_link\">",
"     tobramycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?1/24/1413/abstract/6\">",
"     6",
"    </a>",
"    ]. Strains appear to be variably sensitive to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?1/24/1413/abstract/5\">",
"     5",
"    </a>",
"    ], and clinical failures have occurred with erythromycin treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?1/24/1413/abstract/2,26\">",
"     2,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Intravenous penicillin is the treatment of choice, and prompt therapy can prevent severe complications. Empiric therapy should be immediately begun in patients with a compatible clinical presentation and exposure history, since laboratory confirmation is difficult and may take several days.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest the following treatment regimens:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Adults",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intravenous penicillin (200,000 units every four hours) for five to seven days, followed if clinically improving by oral penicillin or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"       ampicillin",
"      </a>",
"      (500 mg four times per day) for seven days.",
"     </li>",
"     <li>",
"      In patients with penicillin allergy, alternative treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"       tetracycline",
"      </a>",
"      (500 mg orally four times a day) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      (100 mg orally or intravenously twice daily)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Children",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intravenous penicillin (20,000 to 50,000 units per kg per day divided in six doses) to a maximum of 1.2 million units per day. Children who do not require hospitalization can be treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/46/23269?source=see_link\">",
"       penicillin V",
"      </a>",
"      (25",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day orally in three or four divided doses). Duration of treatment is 7 to 10 days.",
"     </li>",
"     <li>",
"      In patients with penicillin allergy, in whom RBF is a serious consideration, alternative treatment is with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      . Although",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"       tetracycline",
"      </a>",
"      can cause dental staining when administered to children, the risk of dental staining with doxycycline is minimal if a short course is administered. Children weighing more than 45 kg should receive the adult dose; smaller children should receive 2 to 4",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      in two divided doses.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/9/18583?source=see_link\">",
"     Streptomycin",
"    </a>",
"    is an alternative therapy in both adults and children with RBF. However, several limitations make its use impractical for the treatment of RBF, including: drug-related toxicity, the need for parenteral administration, and that many pharmacies do not stock streptomycin, making it difficult to obtain promptly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical course of rat-bite fever can be rapid and fatal. As a result, prevention of severe disease depends upon increasing the awareness of appropriate risk-reduction activities and possible symptoms of RBF among persons who have exposure to rats.",
"   </p>",
"   <p>",
"    A three-day course of oral penicillin (2 g per day in adults; 25,000 to 50,000 units per kg per day in children) is reasonable following a rat bite, although efficacy of antimicrobial prophylaxis is unknown.",
"   </p>",
"   <p>",
"    Measures to limit the incidence of RBF include eradication of rats in urban areas, avoidance of unpasteurized milk and potentially contaminated water, and the use of gloves by laboratory workers when handling rodents or cleaning rat cages.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14277368\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rat-bite fever is a rarely diagnosed, systemic illness caused by infection with either Streptobacillus moniliformis or Spirillum minus. S. moniliformis causes most cases of the disease in the United States; S. minus causes rat bite fever primarily in Asia, although it probably is present worldwide. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Human infection can result from a bite or scratch from an infected or colonized rat, handling of an infected rat, or ingestion of food or water contaminated with infected rat feces. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The symptoms of rat-bite fever start abruptly with fever, myalgias, arthralgias, vomiting, and headache followed by a maculopapular rash on the extremities. Polyarthritis occurs in approximately half of patients. Complications include meningitis, endocarditis, pneumonia, and multiorgan failure. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis is established through culturing of blood or synovial fluid specimens; blood cultures should be held for 21 days. No serologic testing is available. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Intravenous penicillin is the treatment of choice. Empiric therapy should be immediately begun in patients with a compatible clinical presentation and exposure history, since laboratory confirmation is difficult and may take several days. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A three-day course of oral penicillin (2 g per day in adults; 25,000 to 50,000 units per kg per day in children) is reasonable following a rat bite, although efficacy of antimicrobial prophylaxis is unknown. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/24/1413/abstract/1\">",
"      Anderson LC, Leary SL, Manning PJ. Rat-bite fever in animal research laboratory personnel. Lab Anim Sci 1983; 33:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/24/1413/abstract/2\">",
"      Centers for Disease Control and Prevention (CDC). Fatal rat-bite fever--Florida and Washington, 2003. MMWR Morb Mortal Wkly Rep 2005; 53:1198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/24/1413/abstract/3\">",
"      Place, EH, Sutton, LE Jr. Erythema athriticum epidemicum (Haverhill fever). Arch Intern Med 1934; 54:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/24/1413/abstract/4\">",
"      McEvoy MB, Noah ND, Pilsworth R. Outbreak of fever caused by Streptobacillus moniliformis. Lancet 1987; 2:1361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/24/1413/abstract/5\">",
"      Centers for Disease Control and Prevention (CDC). Rat-bite fever--New Mexico, 1996. MMWR Morb Mortal Wkly Rep 1998; 47:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/24/1413/abstract/6\">",
"      Torres L, L&oacute;pez AI, Escobar S, et al. Bacteremia by Streptobacillus moniliformis: first case described in Spain. Eur J Clin Microbiol Infect Dis 2003; 22:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/24/1413/abstract/7\">",
"      Pins MR, Holden JM, Yang JM, et al. Isolation of presumptive Streptobacillus moniliformis from abscesses associated with the female genital tract. Clin Infect Dis 1996; 22:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/24/1413/abstract/8\">",
"      Rowbotham TJ. Rapid identification of Streptobacillus moniliformis. Lancet 1983; 2:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/24/1413/abstract/9\">",
"      Centers for Disease Control (CDC). Rat-bite fever in a college student--California. MMWR Morb Mortal Wkly Rep 1984; 33:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/24/1413/abstract/10\">",
"      Stehle P, Dubuis O, So A, Dudler J. Rat bite fever without fever. Ann Rheum Dis 2003; 62:894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/24/1413/abstract/11\">",
"      Mandel DR. Streptobacillary fever. An unusual cause of infectious arthritis. Cleve Clin Q 1985; 52:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/24/1413/abstract/12\">",
"      Tandon R, Lee M, Curran E, et al. A 26-year-old woman with a rash on her extremities. Clin Infect Dis 2006; 43:1585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/24/1413/abstract/13\">",
"      McHugh TP, Bartlett RL, Raymond JI. Rat bite fever: report of a fatal case. Ann Emerg Med 1985; 14:1116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/24/1413/abstract/14\">",
"      Sens MA, Brown EW, Wilson LR, Crocker TP. Fatal Streptobacillus moniliformis infection in a two-month-old infant. Am J Clin Pathol 1989; 91:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/24/1413/abstract/15\">",
"      Shanson DC, Gazzard BG, Midgley J, et al. Streptobacillus moniliformis isolated from blood in four cases of Haverhill fever. Lancet 1983; 2:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/24/1413/abstract/16\">",
"      Shvartsblat S, Kochie M, Harber P, Howard J. Fatal rat bite fever in a pet shop employee. Am J Ind Med 2004; 45:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/24/1413/abstract/17\">",
"      Rordorf T, Z&uuml;ger C, Zbinden R, et al. Streptobacillus moniliformis endocarditis in an HIV-positive patient. Infection 2000; 28:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/24/1413/abstract/18\">",
"      Chen PL, Lee NY, Yan JJ, et al. Prosthetic valve endocarditis caused by Streptobacillus moniliformis: a case of rat bite fever. J Clin Microbiol 2007; 45:3125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/24/1413/abstract/19\">",
"      Wang TK, Wong SS. Streptobacillus moniliformis septic arthritis: a clinical entity distinct from rat-bite fever? BMC Infect Dis 2007; 7:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/24/1413/abstract/20\">",
"      Dendle C, Woolley IJ, Korman TM. Rat-bite fever septic arthritis: illustrative case and literature review. Eur J Clin Microbiol Infect Dis 2006; 25:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/24/1413/abstract/21\">",
"      Boot R, Oosterhuis A, Thuis HC. PCR for the detection of Streptobacillus moniliformis. Lab Anim 2002; 36:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/24/1413/abstract/22\">",
"      Carbeck RB, Murphy JF, Britt EM. Streptobacillary rat-bite fever with massive pericardial effusion. JAMA 1967; 201:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/24/1413/abstract/23\">",
"      Taber LH, Feigin RD. Spirochetal infections. Pediatr Clin North Am 1979; 26:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/24/1413/abstract/24\">",
"      Raffin BJ, Freemark M. Streptobacillary rat-bite fever: a pediatric problem. Pediatrics 1979; 64:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/24/1413/abstract/25\">",
"      Ojukwu IC, Christy C. Rat-bite fever in children: case report and review. Scand J Infect Dis 2002; 34:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/24/1413/abstract/26\">",
"      Hagelskjaer L, S&oslash;rensen I, Randers E. Streptobacillus moniliformis infection: 2 cases and a literature review. Scand J Infect Dis 1998; 30:309.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5528 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-61.234.146.186-B64CF0B05F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_24_1413=[""].join("\n");
var outline_f1_24_1413=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14277368\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Recommendations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Adults",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14277368\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/5528\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5528|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/24/24960\" title=\"picture 1\">",
"      Streptobacillus moniliformis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/21/2393?source=related_link\">",
"      Rabies immune globulin and vaccine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/24/28038?source=related_link\">",
"      Soft tissue infections due to dog and cat bites",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_24_1414="Propranolol and hydrochlorothiazide: Patient drug information";
var content_f1_24_1414=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Propranolol and hydrochlorothiazide: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/30/29158?source=see_link\">",
"     see \"Propranolol and hydrochlorothiazide: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10019926\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700256",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not stop taking this drug all of a sudden. If you do, chest pain that is worse and in some cases heart attack may occur. The risk may be greater if you have certain types of heart disease. To avoid side effects, you will want to slowly stop this drug  as ordered by your doctor. Call your doctor right away if you have new or worse chest pain or if other heart problems occur.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10019928\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691888",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat high blood pressure.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10019927\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702813",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to propranolol, hydrochlorothiazide, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701385",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a sulfa (sulfonamide) allergy, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703315",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Asthma, very bad kidney disease, very bad lung disease, very weak heart, or slow heartbeat without a working pacemaker.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10019932\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697043",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may hide the signs of low blood sugar. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697204",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor. This drug may raise blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697169",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any blood flow problems, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697307",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have mental illness, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697312",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have myasthenia gravis, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a weak heart, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698416",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure and heart rate checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697627",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using OTC products that may raise blood pressure. These include cough or cold drugs, diet pills, stimulants, ibuprofen or like products, and some natural products or aids.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696701",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Be careful in hot weather. Drink lots of fluids to stop fluid loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Watch for gout attacks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10019933\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698217",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low potassium levels like muscle pain or weakness, muscle cramps, or a heartbeat that does not feel normal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697963",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in sex ability.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10019935\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699072",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low potassium.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698650",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you have too much sweat, fluid loss, throwing up, or loose stools. This may lead to low blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10019930\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695872",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause you to pass urine more often. To keep from having sleep problems, try to take before 6 pm.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695322",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Long-acting products: Swallow whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10019931\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10019936\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature. Do not freeze.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10019937\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11005 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-2959C7380A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_24_1414=[""].join("\n");
var outline_f1_24_1414=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019926\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019928\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019927\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019932\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019933\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019935\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019930\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019931\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019936\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019937\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?28/30/29158?source=related_link\">",
"      Propranolol and hydrochlorothiazide: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_24_1415="Ear compression dressing";
var content_f1_24_1415=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F64891&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F64891&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 544px\">",
"   <div class=\"ttl\">",
"    Ear compression dressing",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 524px; height: 556px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Place sterile gauze with a central cut out to provide padding behind the ear.",
"    <br>",
"     (B) Mold&nbsp;petrolatum-impregnated gauze or saline-soaked cotton balls within the contours of the auricle. If the skin was incised, this portion of the dressing needs to reapproximate the skin at the incision site.",
"     <br>",
"      (C) Place sterile gauze over the entire ear.",
"      <br>",
"       (D) Wrap the ear and head with sterile, rolled gauze to hold the dressing in place.",
"       <div class=\"footnotes\">",
"       </div>",
"       <div class=\"reference\">",
"        Reproduced with permission from: Martinez NJ, Friedman MJ. External ear procedures. In: Textbook of Pediatric Emergency Procedures, 2nd Edition, King C, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia, 2008. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"       </div>",
"       <div class=\"contractual\">",
"        <br/>",
"        <a href=\"file://www.lww.com\">",
"         file://www.lww.com",
"        </a>",
"       </div>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_24_1415=[""].join("\n");
var outline_f1_24_1415=null;
var title_f1_24_1416="Asymptomatic hyperuricemia";
var content_f1_24_1416=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Asymptomatic hyperuricemia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/24/1416/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/24/1416/contributors\">",
"     Michael A Becker, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/24/1416/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/24/1416/contributors\">",
"     H Ralph Schumacher, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/24/1416/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/24/1416/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/24/1416/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 9, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Asymptomatic hyperuricemia is the term applied to settings in which the serum urate concentration is elevated but in which neither symptoms nor signs of urate crystal deposition (gout) have occurred. Although gout may develop in a hyperuricemic individual at any point, it is likely that two-thirds or more of hyperuricemic individuals will remain asymptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?1/24/1416/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. The implications of hyperuricemia may be broadly regarded as those related to urate or uric acid crystal deposition and as those emerging from crystal deposition-unrelated associations of hyperuricemia with important disorders, including hypertension, chronic kidney disease, cardiovascular disease, and the insulin resistance syndrome.",
"   </p>",
"   <p>",
"    The etiology and management of asymptomatic hyperuricemia will be reviewed here. Gout, uric acid renal diseases, and uric acid nephrolithiasis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/49/4890?source=see_link\">",
"     \"Clinical manifestations and diagnosis of gout\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/24/17800?source=see_link\">",
"     \"Treatment of acute gout\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/26/36266?source=see_link\">",
"     \"Prevention of recurrent gout\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/57/27541?source=see_link\">",
"     \"Uric acid renal diseases\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/62/3047?source=see_link\">",
"     \"Uric acid nephrolithiasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The statistical definition of hyperuricemia is difficult to accept because of non-normal distribution of serum urate concentrations in most populations. For purposes relating to urate crystal deposition, a definition of hyperuricemia based upon the solubility limit of urate in body fluids (ie, the concentration at which a state of supersaturation for urate is reached in the serum) is appropriate. This physicochemical definition corresponds to urate concentrations exceeding about 7",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (416",
"    <span class=\"nowrap\">",
"     micromol/L),",
"    </span>",
"    as measured by automated enzymatic (uricase) methods in routine clinical laboratory use. These values are approximately 1",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (60",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    lower than those obtained with colorimetric methods.",
"   </p>",
"   <p>",
"    A definition of hyperuricemia appropriate to the non-crystal deposition associations of hyperuricemia with the conditions listed above is more problematic for two reasons: first, the high prevalence of urate values exceeding saturation but within two standard deviations of the population mean (for example, an estimated 5 to 8 percent in adult white males in the US and 25 percent in Taiwan Chinese males [",
"    <a class=\"abstract\" href=\"UTD.htm?1/24/1416/abstract/6\">",
"     6",
"    </a>",
"    ]), and second, the fact that associations of serum urate levels with cardiovascular and other disorders are manifested at concentrations that are clearly subsaturating [",
"    <a class=\"abstract\" href=\"UTD.htm?1/24/1416/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Classification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Persistent hyperuricemia is a common biochemical abnormality that results from excessive urate production",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    from diminished renal uric acid excretion [",
"    <a class=\"abstract\" href=\"UTD.htm?1/24/1416/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/42/24230?source=see_link\">",
"     \"Uric acid balance\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Persistent hyperuricemia can be divided into two categories:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary hyperuricemia, which usually lasts indefinitely, refers to urate supersaturation arising in the absence of coexisting diseases or drugs that alter uric acid production or excretion.",
"     </li>",
"     <li>",
"      Secondary hyperuricemia refers to excessive urate production (",
"      <a class=\"graphic graphic_table graphicRef80891 \" href=\"UTD.htm?5/49/5916\">",
"       table 1",
"      </a>",
"      ) or to diminished renal clearance (",
"      <a class=\"graphic graphic_table graphicRef66799 \" href=\"UTD.htm?43/14/44267\">",
"       table 2",
"      </a>",
"      ) that is the result of another disease, drug, dietary product, or toxin.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary hyperuricemia in men frequently begins at puberty, when the lower serum urate levels characteristic of children rise into the adult male range. Normal adult male values exceed those in women of reproductive age due to enhancement by estrogenic compounds of renal urate clearance [",
"    <a class=\"abstract\" href=\"UTD.htm?1/24/1416/abstract/9\">",
"     9",
"    </a>",
"    ], an effect that is probably mediated by inhibition of renal urate reabsorption by organic anion transporters [",
"    <a class=\"abstract\" href=\"UTD.htm?1/24/1416/abstract/10\">",
"     10",
"    </a>",
"    ]. Thus, hyperuricemia in women is usually delayed until after menopause; at that point, serum urate values in normal women increase and approximate those in normal men of corresponding age. There is a lesser rise in urate levels in postmenopausal women treated with hormone replacement therapy.",
"   </p>",
"   <p>",
"    Although the incidence of gout increases with increasing age in both men and women [",
"    <a class=\"abstract\" href=\"UTD.htm?1/24/1416/abstract/11,12\">",
"     11,12",
"    </a>",
"    ], the incidence rate is appreciable from age 30 in men and only after about age 50 in women. Thus, the clinical manifestations of hyperuricemia in both men and women occur, on average, about two decades later than the initial physiologic increase in serum urate concentration. This observation suggests that there is a lengthy period of asymptomatic hyperuricemia preceding the occurrence of gout.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     POTENTIAL CONSEQUENCES OF HYPERURICEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three major crystal deposition-related disorders associated with hyperuricemia: gout, urolithiasis, and urate nephropathy. Although asymptomatic hyperuricemia was formerly regarded as the initial state in the classically defined progression of gout, preceding acute gouty arthritis, intercritical gout, and chronic tophaceous gout, epidemiologic studies have demonstrated that acute gouty arthritis, uric acid urolithiasis, tophus formation, and chronic urate nephropathy are relatively infrequent occurrences even in individuals with longstanding hyperuricemia [",
"    <a class=\"abstract\" href=\"UTD.htm?1/24/1416/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/49/4890?source=see_link\">",
"     \"Clinical manifestations and diagnosis of gout\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/57/27541?source=see_link\">",
"     \"Uric acid renal diseases\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/62/3047?source=see_link\">",
"     \"Uric acid nephrolithiasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several longitudinal studies have documented an elevated risk of gouty arthritis and urolithiasis with increasing degrees of hyperuricemia and hyperuricosuria, respectively. With the advent of more sensitive imaging techniques, especially ultrasound scanning guiding joint aspiration, the presence of crystals suggested by imaging analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/24/1416/abstract/13\">",
"     13",
"    </a>",
"    ] and confirmed, in some cases, by aspiration and polarized light microscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/24/1416/abstract/14\">",
"     14",
"    </a>",
"    ] has revealed urate crystal deposition in the absence of clinical symptoms that define gout as a symptomatic disorder. Some of these studies have suggested use of such techniques for the evaluation of patients with longstanding &ldquo;asymptomatic hyperuricemia&rdquo; or with unusually high urate levels. However, it has not been resolved whether these findings suggest the need for a new definition of gout and whether symptomatically silent urate deposition is associated with damage over time to the musculoskeletal system or even an indication of increased likelihood of associated comorbid diseases.",
"   </p>",
"   <p>",
"    Hyperuricemia, although clearly associated with hypertension, chronic kidney disease, cardiovascular disease, and components of the insulin resistance syndrome, has not been established as a causal factor in any of these disorders. With the exception of acute uric acid nephropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/24/1416/abstract/15\">",
"     15",
"    </a>",
"    ], the initial clinical manifestations of urate or uric acid crystal deposition are not life-threatening and are readily treatable. This observation, plus the lack of an established causal role of hyperuricemia in chronic kidney disease [",
"    <a class=\"abstract\" href=\"UTD.htm?1/24/1416/abstract/4,16\">",
"     4,16",
"    </a>",
"    ] and the other associated disorders, has restrained enthusiasm in the US for prophylactic antihyperuricemic drug therapy in the vast majority of individuals with asymptomatic hyperuricemia. However, in some countries (eg, Japan) antihyperuricemic drug therapy is recommended for asymptomatic hyperuricemic persons, especially those with associated diseases such as hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?1/24/1416/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A 2013 systematic review has emphasized the lack of adequate evidence to support the use of urate-lowering therapy for the treatment of hypertension in patients with hyperuricemia and the need for further clinical trials in this area [",
"    <a class=\"abstract\" href=\"UTD.htm?1/24/1416/abstract/18\">",
"     18",
"    </a>",
"    ]. This analysis identified only one, small, high quality, randomized trial that addressed this question, in which 30 adolescents newly diagnosed with essential hypertension and hyperuricemia (for age) were randomly assigned to initially receive either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"     allopurinol",
"    </a>",
"    (200 mg twice daily) or placebo for four weeks and were then crossed over to the other arm after a two-week washout period [",
"    <a class=\"abstract\" href=\"UTD.htm?1/24/1416/abstract/19\">",
"     19",
"    </a>",
"    ]. Blood pressure measurements were reduced slightly but statistically significantly during allopurinol treatment. The management of hypertension in adolescents is reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/62/27626?source=see_link\">",
"     \"Treatment of hypertension in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Gout",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is clear evidence of an association between hyperuricemia and gout. One study followed serial serum urate concentrations in 2046 initially healthy men for 15 years [",
"    <a class=\"abstract\" href=\"UTD.htm?1/24/1416/abstract/1\">",
"     1",
"    </a>",
"    ]. The annual incidence of gout was 4.9, 0.5, and 0.1 percent for serum urate levels of greater than 9, 7 to 8.9, and less than 7",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (greater than 535, between 529 and 416, and less than 416",
"    <span class=\"nowrap\">",
"     micromol/L),",
"    </span>",
"    respectively.",
"   </p>",
"   <p>",
"    Similar findings were noted in a second report in which gout occurred in only 12 percent of patients with urate levels between 7 and 7.9",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (416 and 470",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    over a 14-year period [",
"    <a class=\"abstract\" href=\"UTD.htm?1/24/1416/abstract/2\">",
"     2",
"    </a>",
"    ]. Serum urate levels above 9",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (535",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    had a much greater predictive value for the development of gout. However, this degree of hyperuricemia was uncommon in both series, occurring in less than 20 percent of individuals with hyperuricemia.",
"   </p>",
"   <p>",
"    Tophi can occur, usually in patients with antecedent gouty arthritis. However, patients with asymptomatic hyperuricemia who are being treated with nonsteroidal antiinflammatory drugs (NSAIDs) or glucocorticoids for some other reason can develop tophi in the absence of acute gouty arthritis.",
"   </p>",
"   <p>",
"    Risk factors for progression of hyperuricemia to acute gouty arthritis include increased amounts of alcohol consumption (particularly beer and distilled spirits [",
"    <a class=\"abstract\" href=\"UTD.htm?1/24/1416/abstract/20\">",
"     20",
"    </a>",
"    ]), high levels of meat and seafood ingestion [",
"    <a class=\"abstract\" href=\"UTD.htm?1/24/1416/abstract/21\">",
"     21",
"    </a>",
"    ], diuretic use, hypertension, and obesity [",
"    <a class=\"abstract\" href=\"UTD.htm?1/24/1416/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Urolithiasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increasing rates of urinary uric acid excretion are associated with a higher risk of uric acid and calcium oxalate stone formation. When daily urinary uric acid excretion exceeds 1100 mg (6.5 micromol), the incidence of urolithiasis approaches 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?1/24/1416/abstract/24\">",
"     24",
"    </a>",
"    ]. However, this level of uric acid overexcretion is uncommon. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/62/3047?source=see_link\">",
"     \"Uric acid nephrolithiasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/53/33626?source=see_link\">",
"     \"Risk factors for calcium stones in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Chronic kidney disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there is an association between hyperuricemia and chronic kidney disease [",
"    <a class=\"abstract\" href=\"UTD.htm?1/24/1416/abstract/7\">",
"     7",
"    </a>",
"    ], the deterioration in renal function has generally been thought to be attributable to risk factors other than chronic hyperuricemia. The hyperuricemia that is nearly invariable in chronic kidney disease is due to a reduction in the efficiency of urate excretion and is unaccompanied by hyperuricosuria. This is in contrast to acute uric acid nephropathy as part of the tumor lysis and related syndromes in which urate overproduction is the primary abnormality, leading to enhanced urate excretion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/57/27541?source=see_link\">",
"     \"Uric acid renal diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the past, persistent hyperuricemia was thought to cause (uncommonly) a slowly progressive form of chronic renal failure called urate nephropathy in which the deposition of urate in the renal interstitium results in an inflammatory reaction and in progressive tubulointerstitial injury. Many of these patients had tophi, and the renal pathologic changes could be viewed as renal tophi. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/57/27541?source=see_link\">",
"     \"Uric acid renal diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It was suggested that hyperuricemia is of no clinical importance with respect to chronic kidney disease until serum urate levels exceed at least 13",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (773",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    in men and 10",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (595",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    in women, levels that are uncommon and beyond which insufficient data were available to exclude a nephrotoxic effect of hyperuricemia [",
"    <a class=\"abstract\" href=\"UTD.htm?1/24/1416/abstract/4\">",
"     4",
"    </a>",
"    ]. However, tophaceous gout has become a less frequent problem, and the chronic kidney disease that is relatively frequent over time in gout patients could reflect consequences of chronic hyperuricemia unrelated to crystal deposition [",
"    <a class=\"abstract\" href=\"UTD.htm?1/24/1416/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among patients with gout and chronic kidney disease, there are some who have a bland urine sediment and hyperuricemia out of proportion to the degree of renal insufficiency. Although these findings are compatible with urate or a &ldquo;hyperuricemic&rdquo; nephropathy, such patients may have lead intoxication [",
"    <a class=\"abstract\" href=\"UTD.htm?1/24/1416/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/36/5705?source=see_link\">",
"     \"Lead nephropathy and lead-related nephrotoxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An elevation in the serum urate concentration out of proportion to the degree of renal insufficiency has been defined as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?1/24/1416/abstract/26\">",
"     26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Greater than 9",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (535",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      if the plasma creatinine concentration is &le;1.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (132",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"     </li>",
"     <li>",
"      Greater than 10",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (595",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      if the serum creatinine concentration is between 1.5 and 2",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (132 to 176",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"     </li>",
"     <li>",
"      Greater than 12",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (714",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      with more advanced renal failure",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Relation to cardiovascular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The possible relationship between hyperuricemia and cardiovascular disease is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/48/33546?source=see_link&amp;anchor=H34#H34\">",
"     \"Predictors of survival in heart failure due to systolic dysfunction\", section on 'Hyperuricemia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/37/34394?source=see_link&amp;anchor=H1265380#H1265380\">",
"     \"Overview of the possible risk factors for cardiovascular disease\", section on 'Uric acid'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Decisions regarding pharmacologic treatment of asymptomatic hyperuricemia should be based upon an estimate of the risk in each individual for the development of gouty arthritis, tophi, uric acid or calcium oxalate stones, chronic renal insufficiency, or acute uric acid nephropathy. This estimated risk should be weighed against the potential benefits and risks of life-long drug treatment, since primary hyperuricemia usually persists indefinitely. The risks of therapy include rare but potentially severe, even life-threatening toxic reactions to agents such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"     allopurinol",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?1/24/1416/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/57/30614?source=see_link\">",
"     \"Hypersensitivity vasculitis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the author&rsquo;s opinion, urate-lowering treatment for asymptomatic hyperuricemia or for upper normal range serum urate values is unwarranted except in one of the unusual circumstances discussed below or in the setting of a randomized controlled clinical interventional trial likely to contribute to delineating the relationship of hyperuricemia to one of the associated disorders discussed above.",
"   </p>",
"   <p>",
"    Discovery of asymptomatic hyperuricemia should, however, prompt an appropriately limited and focused clinical and biochemical evaluation aimed at identifying the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients at particularly high risk for gouty arthritis, tophi, or urolithiasis who warrant antihyperuricemic treatment",
"     </li>",
"     <li>",
"      Individuals whose hyperuricemia is a sign of an underlying disorder or environmental exposure requiring specific treatment",
"     </li>",
"     <li>",
"      Hyperuricemia-inducing drugs or toxins that can be removed or substituted, with relief or diminution of the hyperuricemic state",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If hyperuricemia is persistent, a thorough history, physical examination, and laboratory evaluation should be performed and directed at discovering potentially treatable causes of hyperuricemia. Examples include lymphoproliferative and myeloproliferative disorders, psoriasis, vitamin B12 deficiency, preeclampsia, and lead nephropathy (or lead exposure) (",
"    <a class=\"graphic graphic_table graphicRef80891 \" href=\"UTD.htm?5/49/5916\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef66799 \" href=\"UTD.htm?43/14/44267\">",
"     table 2",
"    </a>",
"    ). (See appropriate topic reviews.)",
"   </p>",
"   <p>",
"    If the above evaluation for causes of secondary hyperuricemia is normal, a 24-hour urine specimen can be collected, especially in men presenting prior to age 30 and women prior to menopause. A daily urine collection should be done while the individual is receiving a standard diet, excluding alcohol and drugs known to affect uric acid metabolism. (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?20/41/21151?source=see_link\">",
"     \"Patient information: Collection of a 24-hour urine specimen (Beyond the Basics)\"",
"    </a>",
"    .) Measurement of uric acid and creatinine in this specimen will, in persons with stable and normal renal function, usually distinguish between uric acid overproduction (with hyperuricosuria defined as urinary uric acid excretion greater than 800",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    [4.8",
"    <span class=\"nowrap\">",
"     mmol/day]",
"    </span>",
"    or 12",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    [71",
"    <span class=\"nowrap\">",
"     micromol/kg",
"    </span>",
"    per day]) and reduced urinary uric acid clearance (with normal urinary uric acid excretion) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/24/1416/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is important to appreciate that &ldquo;underexcretors&rdquo; actually have a normal rate of urinary uric acid excretion since this is required to maintain the steady state in which production and clearance are relatively equal. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/48/11018?source=see_link&amp;anchor=H838162389#H838162389\">",
"     \"General principles of disorders of water balance (hyponatremia and hypernatremia) and sodium balance (hypovolemia and edema)\", section on 'The steady state'",
"    </a>",
"    .) It is the reduced efficiency of urate excretion that obligates a higher serum urate concentration to achieve a rate of urinary uric acid excretion that matches production. Similar considerations apply to diuretic therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/26/29094?source=see_link\">",
"     \"Diuretic-induced hyperuricemia and gout\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The distinction between overproduction and underexcretion serves two purposes: it can guide further investigation of the underlying cause of hyperuricemia, and, if treatment is necessary, it will be useful in directing the choice of antihyperuricemic medication.",
"   </p>",
"   <p>",
"    The vast majority of hyperuricemic individuals (80 to 90 percent) demonstrate excess dietary purine consumption, urate underexcretion, or both. The remainder exhibit overproduction of urate from endogenous sources. These situations may be distinguished in the following way:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The fractional excretion of uric acid can be measured, preferably on a 24-hour urine collection. Underexcretion is defined as a fractional excretion of uric acid below 6 percent. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/17/8472?source=see_link\">",
"       \"Fractional excretion of sodium, urea, and other molecules in acute kidney injury (acute renal failure)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If hyperuricosuria is present, the urine collection can be repeated after three to five days on an isocaloric, reduced purine diet containing 1",
"      <span class=\"nowrap\">",
"       gram/kg",
"      </span>",
"      protein daily from dairy sources and excluding alcohol, meat, seafood, and medications known to affect uric acid metabolism (",
"      <a class=\"graphic graphic_table graphicRef51328 \" href=\"UTD.htm?5/16/5387\">",
"       table 3",
"      </a>",
"      ). If urate excretion is greater than 670",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      (4",
"      <span class=\"nowrap\">",
"       mmol/day)",
"      </span>",
"      on such a diet, inherited causes of overproduction such as various enzyme defects, disordered adenosine triphosphate (ATP) metabolism, or disorders resulting in increased rates of cell turnover should be considered before making a diagnosis of primary hyperuricemia (",
"      <a class=\"graphic graphic_table graphicRef80891 \" href=\"UTD.htm?5/49/5916\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      If uric acid excretion and serum urate levels decline to normal levels on a reduced purine diet, excess dietary purine consumption is confirmed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most patients with underexcretion of urate and with a normal glomerular filtration rate (GFR) have no other demonstrable abnormality in renal function. The defect in renal urate transport (which could be manifested functionally either as reduced secretion or as enhanced reabsorption) may be acquired (",
"    <a class=\"graphic graphic_table graphicRef66799 \" href=\"UTD.htm?43/14/44267\">",
"     table 2",
"    </a>",
"    ), intrinsic, an inherited trait, or secondary to reduced renal perfusion (eg, diuretics). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/42/24230?source=see_link\">",
"     \"Uric acid balance\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;As stated above, in the absence of unequivocal evidence for a causal role of this chemical aberration in one or more of the non-crystal deposition disorders listed, it seems appropriate to maintain the view that hyperuricemia is not a disease. This view is strengthened by the fact that monosodium urate or uric acid crystal deposition, not urate itself, is the essential pathophysiologic link between hyperuricemia and clinical manifestations such as gouty arthritis, uric acid urolithiasis, and tophus formation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/24/1416/abstract/29\">",
"     29",
"    </a>",
"    ]. Thus, hyperuricemia can be viewed as a necessary (although not usually sufficient) predisposing factor for the narrow range of clinical manifestations of gout.",
"   </p>",
"   <p>",
"    Antihyperuricemic drug therapy for the great majority of individuals with asymptomatic hyperuricemia is",
"    <strong>",
"     not justifiable",
"    </strong>",
"    by",
"    <span class=\"nowrap\">",
"     risk/benefit",
"    </span>",
"    analysis. As mentioned above, gouty arthritis is readily treatable and reversible if it occurs. Similarly, prophylaxis against stone disease is not warranted in most individuals, but therapy should be started after discovery of a stone. The primary therapeutic modality in hyperuricemic but non-gouty individuals who experience a urinary tract stone is urinary alkalinization with potassium citrate or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/35/7731?source=see_link\">",
"     potassium bicarbonate",
"    </a>",
"    , not",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"     allopurinol",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/62/3047?source=see_link\">",
"     \"Uric acid nephrolithiasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Three specific circumstances warrant at least consideration for the institution of antihyperuricemic treatment in asymptomatic subjects:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Persistent hyperuricemia in the infrequent patients with sustained serum urate concentrations greater than 13",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (773",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      in men and 10",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (595",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      in women is one such circumstance. These high values may carry some nephrotoxic risk, perhaps related to the likelihood of some component of uric acid overproduction. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/26/36266?source=see_link&amp;anchor=H7#H7\">",
"       \"Prevention of recurrent gout\", section on 'Indications'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      This recommendation does",
"      <strong>",
"       not",
"      </strong>",
"      generally apply to patients with heart failure who may develop marked hyperuricemia due to renal hypoperfusion and to reduced urate excretion. Such patients typically have advanced heart failure with limited life expectancy (unless they undergo transplantation) and are, therefore, at low risk for chronic urate nephropathy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/26/29094?source=see_link\">",
"       \"Diuretic-induced hyperuricemia and gout\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Excretion of urinary uric acid in excess of 1100 mg (6.5 mmol) daily is associated with a 50 percent risk of uric acid calculi [",
"      <a class=\"abstract\" href=\"UTD.htm?1/24/1416/abstract/24,30\">",
"       24,30",
"      </a>",
"      ]. Management of these individuals should begin with dietary purine restriction.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"       Allopurinol",
"      </a>",
"      should be used if dietary restriction does not reduce uric acid excretion to less than 1000",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      (5.9",
"      <span class=\"nowrap\">",
"       mmol/day).",
"      </span>",
"      The dose should be adjusted to reduce uric acid excretion below 800",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      (4.8",
"      <span class=\"nowrap\">",
"       mmol/day).",
"      </span>",
"     </li>",
"     <li>",
"      Patients about to receive radiotherapy or chemotherapy that is likely to result in extensive tumor cytolysis should be treated to prevent acute uric acid nephropathy and other manifestations of tumor lysis syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?1/24/1416/abstract/15\">",
"       15",
"      </a>",
"      ]. Preventive therapy in patients at risk includes intravenous hydration and either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"       allopurinol",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/54/34661?source=see_link\">",
"       rasburicase",
"      </a>",
"      (recombinant urate oxidase). These issues are discussed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/20/3402?source=see_link&amp;anchor=H21712037#H21712037\">",
"       \"Tumor lysis syndrome: Prevention and treatment\", section on 'Clinical impact of TLS'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H817689\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hyperuricemia is difficult to define by usual statistical methods because of the non-normal distribution of serum urate concentrations in most populations. For purposes relating to urate crystal deposition, a physiochemical definition of hyperuricemia based upon the solubility limit of urate in body fluids is appropriate. This corresponds to urate concentrations exceeding about 7",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (416",
"      <span class=\"nowrap\">",
"       micromol/L),",
"      </span>",
"      as measured by automated enzymatic (uricase) methods. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definitions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Primary hyperuricemia refers to urate supersaturation arising in the absence of coexisting diseases or drugs that alter uric acid production or excretion. Secondary hyperuricemia is a common biochemical abnormality that results from excessive urate production (",
"      <a class=\"graphic graphic_table graphicRef80891 \" href=\"UTD.htm?5/49/5916\">",
"       table 1",
"      </a>",
"      )",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      from diminished renal uric acid excretion (",
"      <a class=\"graphic graphic_table graphicRef66799 \" href=\"UTD.htm?43/14/44267\">",
"       table 2",
"      </a>",
"      ) due to another disease, drug, dietary product, or toxin. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Classification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Primary hyperuricemia in men frequently begins at puberty. Normal adult male values exceed those in women of reproductive age due to enhancement by estrogenic compounds of renal urate clearance. Thus, hyperuricemia in women is usually delayed until after menopause; at that point, serum urate values in normal women increase and approximate those in normal men of corresponding age. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are three major crystal deposition-related disorders associated with hyperuricemia: gout, urolithiasis, and urate nephropathy. Although asymptomatic hyperuricemia was formerly regarded as the initial state in the classically defined progression of gout, acute gouty arthritis, uric acid urolithiasis, tophus formation, and chronic urate nephropathy are relatively infrequent occurrences even in individuals with longstanding hyperuricemia. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Potential consequences of hyperuricemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is an elevated risk of gouty arthritis and urolithiasis with increasing degrees of hyperuricemia and hyperuricosuria, respectively. Hyperuricemia, although clearly associated with hypertension, chronic kidney disease, cardiovascular disease, and components of the insulin resistance syndrome, has not been established as a causal factor in any of these disorders. With the exception of acute uric acid nephropathy, the initial clinical manifestations of urate or uric acid crystal deposition are not life-threatening and are readily treatable. Thus, routine urate-lowering pharmacotherapy for asymptomatic hyperuricemia is not recommended in the US, but this is not a settled issue. In certain countries, antihyperuricemic treatment for some patients with asymptomatic hyperuricemia is recommended. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Gout'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Urolithiasis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Chronic kidney disease'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Potential consequences of hyperuricemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Discovery of asymptomatic hyperuricemia should prompt an appropriately limited and focused clinical and biochemical evaluation aimed at identifying patients at particularly high risk for gouty arthritis, tophi, or urolithiasis who warrant antihyperuricemic treatment; individuals whose hyperuricemia is a sign of an underlying disorder or environmental exposure requiring specific treatment; and hyperuricemia-inducing drugs or toxins that can be removed or substituted, with relief or diminution of the hyperuricemic state. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with persistent hyperuricemia, a thorough history, physical examination, and laboratory evaluation should be performed and directed at discovering potentially treatable causes of hyperuricemia, such as lymphoproliferative and myeloproliferative disorders, psoriasis, vitamin B12 deficiency, preeclampsia, and lead nephropathy (or lead exposure). In patients (particularly men presenting before age 30 or women before menopause) with a negative evaluation for secondary hyperuricemia, a 24-hour urine specimen should be collected while the individual is receiving a standard diet, excluding alcohol and drugs known to affect uric acid metabolism. The distinction between overproduction and underexcretion serves to guide further investigation of the underlying cause of hyperuricemia, and, if treatment is necessary, it will be useful in directing the choice of antihyperuricemic medication. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hyperuricemia itself is not a disease but can be viewed as a necessary (although not usually sufficient) predisposing factor for the narrow range of clinical manifestations of gout. Three specific circumstances warrant further evaluation and intervention and may require the institution of antihyperuricemic treatment in asymptomatic subjects (see",
"      <a class=\"local\" href=\"#H11\">",
"       'Management'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Persistent hyperuricemia in the infrequent patients with sustained serum urate concentrations greater than 13",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (773",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      in men and 10",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (595",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      in women, with the general exception of patients with advanced heart failure",
"     </li>",
"     <li>",
"      Excretion of urinary uric acid in excess of 1100 mg (6.5 mmol) daily, which is associated with a 50 percent risk of uric acid calculi. Initial management of these individuals should begin with dietary purine restriction and should proceed, as necessary, to treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"       allopurinol",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Patients about to receive radiotherapy or chemotherapy that is likely to result in extensive tumor cytolysis, who should be treated to prevent acute uric acid nephropathy and other manifestations of tumor lysis syndrome",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/24/1416/abstract/1\">",
"      Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. Am J Med 1987; 82:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/24/1416/abstract/2\">",
"      Langford HG, Blaufox MD, Borhani NO, et al. Is thiazide-produced uric acid elevation harmful? Analysis of data from the Hypertension Detection and Follow-up Program. Arch Intern Med 1987; 147:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/24/1416/abstract/3\">",
"      Hall AP, Barry PE, Dawber TR, McNamara PM. Epidemiology of gout and hyperuricemia. A long-term population study. Am J Med 1967; 42:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/24/1416/abstract/4\">",
"      Fessel WJ. Renal outcomes of gout and hyperuricemia. Am J Med 1979; 67:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/24/1416/abstract/5\">",
"      Johnson RJ, Feig DI, Herrera-Acosta J, Kang DH. Resurrection of uric acid as a causal risk factor in essential hypertension. Hypertension 2005; 45:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/24/1416/abstract/6\">",
"      Lin KC, Lin HY, Chou P. Community based epidemiological study on hyperuricemia and gout in Kin-Hu, Kinmen. J Rheumatol 2000; 27:1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/24/1416/abstract/7\">",
"      S&aacute;nchez-Lozada LG, Tapia E, Rodr&iacute;guez-Iturbe B, et al. Hemodynamics of hyperuricemia. Semin Nephrol 2005; 25:19.",
"     </a>",
"    </li>",
"    <li>",
"     Wyngaarden JB, Kelley WN. Gout and Hyperuricemia, Grune and Stratton, New York 1976.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/24/1416/abstract/9\">",
"      Ant&oacute;n FM, Garc&iacute;a Puig J, Ramos T, et al. Sex differences in uric acid metabolism in adults: evidence for a lack of influence of estradiol-17 beta (E2) on the renal handling of urate. Metabolism 1986; 35:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/24/1416/abstract/10\">",
"      Ljubojevic M, Herak-Kramberger CM, Hagos Y, et al. Rat renal cortical OAT1 and OAT3 exhibit gender differences determined by both androgen stimulation and estrogen inhibition. Am J Physiol Renal Physiol 2004; 287:F124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/24/1416/abstract/11\">",
"      Arromdee E, Michet CJ, Crowson CS, et al. Epidemiology of gout: is the incidence rising? J Rheumatol 2002; 29:2403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/24/1416/abstract/12\">",
"      Mikuls TR, Farrar JT, Bilker WB, et al. Gout epidemiology: results from the UK General Practice Research Database, 1990-1999. Ann Rheum Dis 2005; 64:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/24/1416/abstract/13\">",
"      Puig JG, de Miguel E, Castillo MC, et al. Asymptomatic hyperuricemia: impact of ultrasonography. Nucleosides Nucleotides Nucleic Acids 2008; 27:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/24/1416/abstract/14\">",
"      De Miguel E, Puig JG, Castillo C, et al. Diagnosis of gout in patients with asymptomatic hyperuricaemia: a pilot ultrasound study. Ann Rheum Dis 2012; 71:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/24/1416/abstract/15\">",
"      Kjellstrand CM, Cambell DC 2nd, von Hartitzsch B, Buselmeier TJ. Hyperuricemic acute renal failure. Arch Intern Med 1974; 133:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/24/1416/abstract/16\">",
"      Liang MH, Fries JF. Asymptomatic hyperuricemia: the case for conservative management. Ann Intern Med 1978; 88:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/24/1416/abstract/17\">",
"      Yamanaka H, Japanese Society of Gout and Nucleic Acid Metabolism. Japanese guideline for the management of hyperuricemia and gout: second edition. Nucleosides Nucleotides Nucleic Acids 2011; 30:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/24/1416/abstract/18\">",
"      Gois PH, Souza ER. Pharmacotherapy for hyperuricemia in hypertensive patients. Cochrane Database Syst Rev 2013; 1:CD008652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/24/1416/abstract/19\">",
"      Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA 2008; 300:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/24/1416/abstract/20\">",
"      Choi HK, Atkinson K, Karlson EW, et al. Alcohol intake and risk of incident gout in men: a prospective study. Lancet 2004; 363:1277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/24/1416/abstract/21\">",
"      Choi HK, Atkinson K, Karlson EW, et al. Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med 2004; 350:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/24/1416/abstract/22\">",
"      Lin KC, Lin HY, Chou P. The interaction between uric acid level and other risk factors on the development of gout among asymptomatic hyperuricemic men in a prospective study. J Rheumatol 2000; 27:1501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/24/1416/abstract/23\">",
"      Choi HK, Atkinson K, Karlson EW, Curhan G. Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the health professionals follow-up study. Arch Intern Med 2005; 165:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/24/1416/abstract/24\">",
"      Y&uuml; T, Gutman AB. Uric acid nephrolithiasis in gout. Predisposing factors. Ann Intern Med 1967; 67:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/24/1416/abstract/25\">",
"      Shadick NA, Kim R, Weiss S, et al. Effect of low level lead exposure on hyperuricemia and gout among middle aged and elderly men: the normative aging study. J Rheumatol 2000; 27:1708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/24/1416/abstract/26\">",
"      Murray T, Goldberg M. Chronic interstitial nephritis: etiologic factors. Ann Intern Med 1975; 82:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/24/1416/abstract/27\">",
"      Singer JZ, Wallace SL. The allopurinol hypersensitivity syndrome. Unnecessary morbidity and mortality. Arthritis Rheum 1986; 29:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/24/1416/abstract/28\">",
"      Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984; 76:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/24/1416/abstract/29\">",
"      Becker MA. Clinical aspects of monosodium urate monohydrate crystal deposition disease (gout). Rheum Dis Clin North Am 1988; 14:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/24/1416/abstract/30\">",
"      Yu TF. Urolithiasis in hyperuricemia and gout. J Urol 1981; 126:424.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1669 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-2.133.93.82-84A455F99E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_24_1416=[""].join("\n");
var outline_f1_24_1416=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H817689\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Classification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      POTENTIAL CONSEQUENCES OF HYPERURICEMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Gout",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Urolithiasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Relation to cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H817689\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/1669\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/1669|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/49/5916\" title=\"table 1\">",
"      Secondary uricemia production",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?43/14/44267\" title=\"table 2\">",
"      Secondary uricemia excretion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/16/5387\" title=\"table 3\">",
"      Low purine diet",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/49/4890?source=related_link\">",
"      Clinical manifestations and diagnosis of gout",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/26/29094?source=related_link\">",
"      Diuretic-induced hyperuricemia and gout",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/17/8472?source=related_link\">",
"      Fractional excretion of sodium, urea, and other molecules in acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/48/11018?source=related_link\">",
"      General principles of disorders of water balance (hyponatremia and hypernatremia) and sodium balance (hypovolemia and edema)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/57/30614?source=related_link\">",
"      Hypersensitivity vasculitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/36/5705?source=related_link\">",
"      Lead nephropathy and lead-related nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/37/34394?source=related_link\">",
"      Overview of the possible risk factors for cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?20/41/21151?source=related_link\">",
"      Patient information: Collection of a 24-hour urine specimen (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/48/33546?source=related_link\">",
"      Predictors of survival in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/26/36266?source=related_link\">",
"      Prevention of recurrent gout",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/53/33626?source=related_link\">",
"      Risk factors for calcium stones in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/24/17800?source=related_link\">",
"      Treatment of acute gout",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/62/27626?source=related_link\">",
"      Treatment of hypertension in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/20/3402?source=related_link\">",
"      Tumor lysis syndrome: Prevention and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/42/24230?source=related_link\">",
"      Uric acid balance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/62/3047?source=related_link\">",
"      Uric acid nephrolithiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/57/27541?source=related_link\">",
"      Uric acid renal diseases",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_24_1417="Medroxyprogesterone acetate: Drug information";
var content_f1_24_1417=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Medroxyprogesterone acetate: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?35/25/36245?source=see_link\">",
"    see \"Medroxyprogesterone acetate: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?35/49/36631?source=see_link\">",
"    see \"Medroxyprogesterone acetate: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709035\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F192012\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Depo-Provera&reg;;",
"     </li>",
"     <li>",
"      Depo-Provera&reg; Contraceptive;",
"     </li>",
"     <li>",
"      depo-subQ provera 104&reg;;",
"     </li>",
"     <li>",
"      Provera&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F192013\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Alti-MPA;",
"     </li>",
"     <li>",
"      Apo-Medroxy&reg;;",
"     </li>",
"     <li>",
"      Depo-Prevera&reg;;",
"     </li>",
"     <li>",
"      Depo-Provera&reg;;",
"     </li>",
"     <li>",
"      Dom-Medroxyprogesterone;",
"     </li>",
"     <li>",
"      Gen-Medroxy;",
"     </li>",
"     <li>",
"      Medroxy;",
"     </li>",
"     <li>",
"      Medroxyprogesterone Acetate Injectable Suspension USP;",
"     </li>",
"     <li>",
"      Novo-Medrone;",
"     </li>",
"     <li>",
"      PMS-Medroxyprogesterone;",
"     </li>",
"     <li>",
"      Provera-Pak;",
"     </li>",
"     <li>",
"      Provera&reg;;",
"     </li>",
"     <li>",
"      Teva-Medroxyprogesterone",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F192035\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Contraceptive;",
"     </li>",
"     <li>",
"      Progestin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F192015\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Amenorrhea:",
"     </b>",
"     Oral: 5-10 mg/day for 5-10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Abnormal uterine bleeding:",
"     </b>",
"     Oral: 5-10 mg for 5-10 days starting on day 16 or 21 of cycle",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Contraception:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Depo-Provera&reg; Contraceptive: I.M.: 150 mg every 3 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     depo-subQ provera 104&trade;: SubQ: 104 mg every 3 months (every 12-14 weeks)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Endometriosis (depo-subQ provera 104&trade;):",
"     </b>",
"     SubQ: 104 mg every 3 months (every 12-14 weeks)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Endometrial carcinoma, recurrent or metastatic (adjunctive/palliative treatment) (Depo-Provera&reg;):",
"     </b>",
"     I.M.: 400-1000 mg/week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Accompanying cyclic estrogen therapy, postmenopausal:",
"     </b>",
"     Oral: 5-10 mg for 12-14 consecutive days each month, starting on day 1 or day 16 of the cycle; lower doses may be used if given with estrogen continuously throughout the cycle",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Treatment of paraphilia/hypersexuality (unlabeled use; Reilly, 2000):",
"     </b>",
"     Males (",
"     <b>",
"      Note:",
"     </b>",
"     Avoid use if active pituitary pathology, hepatic failure or thromboembolic disease):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M. (Depo-Provera&reg;): 100-600 mg weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: 100-500 mg daily",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F192028\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?35/49/36631?source=see_link\">",
"      see \"Medroxyprogesterone acetate: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Amenorrhea:",
"     </b>",
"     Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Abnormal uterine bleeding:",
"     </b>",
"     Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Contraception:",
"     </b>",
"     Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Endometriosis:",
"     </b>",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F192016\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F16317858\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F192017\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use is contraindicated with severe impairment. Discontinue with jaundice or if liver function disturbances occur. Consider lower dose or less frequent administration with mild-to-moderate impairment. Use of the contraceptive injection has not been studied in patients with hepatic impairment; consideration should be given to not readminister if jaundice develops",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F191989\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, suspension, as acetate: 150 mg/mL (1 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Depo-Provera&reg;: 400 mg/mL (2.5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Depo-Provera&reg; Contraceptive: 150 mg/mL (1 mL) [contains polysorbate 80]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     depo-subQ provera 104&reg;: 104 mg/0.65 mL (0.65 mL) [contains polysorbate 80]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as acetate: 2.5 mg, 5 mg, 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Provera&reg;: 2.5 mg, 5 mg, 10 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F191974\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F191992\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.M.: Depo-Provera&reg; Contraceptive: Administer first dose during the first 5 days of menstrual period, or within the first 5 days postpartum if not breast-feeding, or at the sixth week postpartum if breast-feeding exclusively. Shake vigorously prior to administration. Administer by deep I.M. injection in the gluteal or deltoid muscle.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     When switching from combined hormonal contraceptives (estrogen plus progestin), the first injection should be on the day after the last active tablet or (at the latest) the day after the final inactive tablet. When switching from other contraceptive methods, ensure continuous contraceptive coverage.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     SubQ: depo-subQ provera 104&trade;: Administer first dose during the first 5 days of menstrual period, or at the sixth week postpartum if breast-feeding. Shake vigorously prior to administration. Administer by SubQ injection in the anterior thigh or abdomen; avoid boney areas and the umbilicus. Administer over 5-7 seconds. Do not rub the injection area. When switching from combined hormonal contraceptives (estrogen plus progestin), the first injection should be within 7 days after the last active pill, or removal of patch or ring. If switching from the I.M. to SubQ formulation, the next dose should be given within the prescribed dosing period for the I.M. injection to assure continuous coverage.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F191991\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Secondary amenorrhea or abnormal uterine bleeding due to hormonal imbalance; reduction of endometrial hyperplasia in nonhysterectomized postmenopausal women receiving conjugated estrogens; prevention of pregnancy; management of endometriosis-associated pain; adjunctive therapy and palliative treatment of recurrent and metastatic endometrial carcinoma",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F9348765\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of low-grade endometrial stromal sarcoma; treatment of paraphilia/hypersexuality",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F192043\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Depo-Provera&reg; may be confused with depo-subQ provera 104&trade;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       MedroxyPROGESTERone may be confused with hydroxyprogesterone caproate, methylPREDNISolone, methylTESTOSTERone",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Provera&reg; may be confused with Covera&reg;, Femara&reg;, Parlodel&reg;, Premarin&reg;, Proscar&reg;, PROzac&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The injectable dosage form is available in different formulations. Carefully review prescriptions to assure the correct formulation and route of administration.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F192033\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse effects as reported with any dosage form; percent ranges presented are noted with the MPA I.M. contraceptive injection:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;5%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness, headache, nervousness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Libido decreased, menstrual irregularities (includes bleeding, amenorrhea, or both)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain/discomfort, weight gain (&gt;10 lbs at 24 months: 38%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 5%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Depression, fatigue, insomnia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Acne, alopecia, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Breast pain, hot flashes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Bloating, nausea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Dysmenorrhea, leukorrhea, vaginitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site reaction (SubQ administration): Atrophy, induration, pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, backache, leg cramp, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Allergic reaction, anaphylaxis, anaphylactoid reactions, angioedema, asthma, blood dyscrasia, bone mineral density decreased, breast cancer, breast changes, cervical cancer, chest pain, chloasma, cholestatic jaundice, deep vein thrombosis, diaphoresis, dyspnea, facial palsy, galactorrhea, glucose tolerance decreased, hirsutism, hoarseness, injection site reactions, jaundice, lack of return to fertility, lactation decreased, melasma, nipple bleeding, optic neuritis, osteoporosis, osteoporotic fractures, paralysis, paresthesia, pulmonary embolus, rectal bleeding, retinal thrombosis, scleroderma, seizure, syncope, tachycardia, thrombophlebitis, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     In addition: Depo-Provera&reg; aqueous suspension: Residual lump, sterile abscess, or skin discoloration at the injection",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F191995\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to medroxyprogesterone or any component of the formulation; history of or current thrombophlebitis or venous thromboembolic disorders (including DVT, PE); cerebral vascular disease; severe hepatic dysfunction or disease; carcinoma of the breast or other estrogen- or progesterone-dependent neoplasia; undiagnosed vaginal bleeding; missed abortion, diagnostic test for pregnancy, pregnancy",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F191978\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylaxis/hypersensitivity reactions: Anaphylaxis or anaphylactoid reactions have been reported with use of the injection; medication for the treatment of hypersensitivity reactions should be available for immediate use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone mineral density loss:",
"     <b>",
"      [U.S. Boxed Warning]: Prolonged use of medroxyprogesterone contraceptive injection may result in a loss of bone mineral density (BMD).  It is not known if use during adolescence or early adulthood will decrease peak bone mass accretion or increase the risk for osteoporotic fractures later in life.  Loss is related to the duration of use, may not be completely reversible on discontinuation of the drug,",
"     </b>",
"     and incidence is not significantly different between the SubQ and I.M. dosage forms. The impact on peak bone mass in adolescents should be weighed against the potential for unintended pregnancies in treatment decision. Consider alternative contraceptive methods in patients at risk for osteoporosis (eg, metabolic bone disease, family history of osteoporosis, chronic use of medications associated with osteoporosis such as corticosteroids).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Breast cancer:",
"     <b>",
"      [U.S. Boxed Warning]: Based on data from the Women&rsquo;s Health Initiative (WHI) studies, an increased risk of invasive breast cancer was observed in postmenopausal women using conjugated estrogens (CE) in combination with medroxyprogesterone acetate (MPA).",
"     </b>",
"     This risk may be associated with duration of use and declines once combined therapy is discontinued (Chlebowski, 2009). The risk of invasive breast cancer was decreased in postmenopausal women with a hysterectomy using CE only, regardless of weight. However, the risk was not significantly decreased in women at high risk for breast cancer (family history of breast cancer, personal history of benign breast disease) (Anderson, 2012). An increase in abnormal mammogram findings has also been reported with estrogen alone or in combination with progestin therapy. Use is contraindicated in patients with known or suspected breast cancer.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dementia:",
"     <b>",
"      [U.S. Boxed Warning]: Estrogens with or without progestin should not be used to prevent dementia. In the Women&rsquo;s Health Initiative Memory Study (WHIMS), an increased incidence of dementia was observed in women &ge;65 years of age taking CE alone or in combination with MPA.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ectopic pregnancy: When used for contraception, the possibility of ectopic pregnancy should be considered in patients with abdominal pain.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Endometrial carcinoma: MPA is used to reduce the risk of endometrial hyperplasia in nonhysterectomized postmenopausal women receiving conjugated estrogens. The use of unopposed estrogen in women with an intact uterus is associated with an increased risk of endometrial cancer. The addition of a progestin to estrogen therapy may decrease the risk of endometrial hyperplasia, a precursor to endometrial cancer. Adequate diagnostic measures, including endometrial sampling if indicated, should be performed to rule out malignancy in postmenopausal women with undiagnosed abnormal vaginal bleeding. Estrogens may exacerbate endometriosis. Malignant transformation of residual endometrial implants has been reported posthysterectomy with unopposed estrogen therapy. Consider adding a progestin in women with residual endometriosis posthysterectomy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ovarian cancer: Postmenopausal estrogen therapy and combined estrogen/progesterone therapy may increase the risk of ovarian cancer; however, the absolute risk to an individual woman is small. Although results from various studies are not consistent, risk does not appear to be significantly associated with the duration, route, or dose of therapy. In one study, the risk decreased after 2 years following discontinuation of therapy (M&oslash;rch, 2009). Although the risk of ovarian cancer is rare, women who are at an increased risk (eg, family history) should be counseled about the association (NAMS, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Retinal vascular thrombosis: Discontinue pending examination in cases of sudden partial or complete vision loss, sudden onset of proptosis, diplopia, or migraine; discontinue permanently if papilledema or retinal vascular lesions are observed on examination.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vaginal bleeding: Unscheduled bleeding/spotting may occur. Presentation of irregular, unresolving vaginal bleeding following previously regular cycles warrants further evaluation including endometrial sampling, if indicated, to rule out malignancy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Weight gain: Contraceptive therapy with medroxyprogesterone commonly results in an average weight gain of ~2.5 kg after 1 year and ~3.7 kg after 2 years of treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Carbohydrate intolerance: May have adverse effects on glucose tolerance; use caution in women with diabetes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease:",
"     <b>",
"      [U.S. Boxed Warning]: Estrogens with or without progestin should not be used to prevent cardiovascular disease.",
"     </b>",
"     Using data from the Women&rsquo;s Health Initiative (WHI) studies, an increased risk of deep vein thrombosis (DVT) and stroke has been reported with CE and an increased risk of DVT, stroke, pulmonary emboli (PE) and myocardial infarction (MI) has been reported with CE with MPA in postmenopausal women. Additional risk factors include diabetes mellitus, hypercholesterolemia, hypertension, SLE, obesity, tobacco use, and/or history of venous thromboembolism (VTE). Risk factors should be managed appropriately; discontinue use if adverse cardiovascular events occur or are suspected. If thrombosis develops with contraceptive treatment, discontinue treatment (unless no other acceptable contraceptive alternative).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Depression: Use with caution in patients with a history of depression.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diseases exacerbated by fluid retention: Use with caution in patients with diseases which may be exacerbated by fluid retention, including asthma, epilepsy, migraine, cardiac, or renal dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic dysfunction: MPA is extensively metabolized in the liver. Discontinue if jaundice develops or if acute or chronic hepatic disturbances occur. Use is contraindicated with severe hepatic disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Osteoporosis: Consider other methods of birth control in women with (or at risk for) osteoporosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Not for use prior to menarche.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Surgical patients: Whenever possible, progestins in combination with estrogens should be discontinued at least 4-6 weeks prior to and for 2 weeks following elective surgery associated with an increased risk of thromboembolism or during periods of prolonged immobilization.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Laboratory changes: The use of estrogens and/or progestins may change the results of some laboratory tests (eg, coagulation factors, lipids, glucose tolerance, binding proteins). The dose, route, and the specific estrogen/progestin influences these changes. In addition, personal risk factors (eg, cardiovascular disease, smoking, diabetes, age) also contribute to adverse events; use of specific products may be contraindicated in women with certain risk factors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Long-term use:",
"     <b>",
"      [U.S. Boxed Warning]: Long-term use (ie, &gt;2 years) should be limited to situations where other birth control methods are inadequate.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Patient education:",
"     <b>",
"      [U.S. Boxed Warning]: Inform patients that injectable contraceptives do not protect against HIV infection or other sexually-transmitted diseases.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Risks vs benefits:",
"     <b>",
"      [U.S. Boxed Warning]: Estrogens with or without progestin should be used for the shortest duration possible at the lowest effective dose consistent with treatment goals.",
"     </b>",
"     Before prescribing estrogen therapy to postmenopausal women, the risks and benefits must be weighed for each patient. Women should be informed of these risks and benefits, as well as possible effects of progestin when added to estrogen therapy. Patients should be reevaluated as clinically appropriate to determine if treatment is still necessary. Available data related to treatment risks are from Women&rsquo;s Health Initiative (WHI) studies, which evaluated oral CE 0.625 mg with or without MPA 2.5 mg relative to placebo in postmenopausal women. Other combinations and dosage forms of estrogens and progestins were not studied.",
"     <b>",
"      Outcomes reported from clinical trials using CE with or without MPA should be assumed to be similar for other doses and other dosage forms of estrogens and progestins until comparable data becomes available.",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F192030\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Induces",
"     </b>",
"     CYP3A4 (weak/moderate)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F191983\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acitretin: May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible. Management: Given the potential for progestin-only preparations to fail to prevent pregnancy during acitretin therapy, such products should not be relied upon. Alternative, nonhormonal forms of contraception must be employed during acitretin therapy.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglutethimide: May increase the metabolism of Progestins. Management: Progestin-containing contraceptives are not recommended; consider the use of alternative, nonhormonal contraceptives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprepitant: May decrease the serum concentration of Contraceptives (Progestins). Management: Alternative or additional methods of contraception should be used both during treatment with aprepitant or fosaprepitant and for at least one month following the last aprepitant/fosaprepitant dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.  Management: Double the oral aripiprazole dose and closely monitor clinical response.  Reduce the oral aripiprazole dose to 10-15 mg/day if the inducer is discontinued. Avoid use of CYP3A4 inducers for more than 14 days with extended-release injectable aripiprazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Artemether: May decrease the serum concentration of Contraceptives (Progestins). Management: Consider the use of an alternative (i.e., non-hormonal) means of contraception in all women of childbearing potential who are using artemether.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atazanavir: May increase the serum concentration of Contraceptives (Progestins).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inducers (Weakly to Moderately Effective) may decrease the serum concentration of Axitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible. Management: Use of alternative, nonhormonal contraceptives is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzodiazepines (metabolized by oxidation): Contraceptives (Progestins) may increase the serum concentration of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bexarotene (Systemic): May decrease the serum concentration of Contraceptives (Progestins). Management: Women of childbearing potential receiving bexarotene should use two reliable forms of contraception (including at least one nonhormonal form).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the serum concentration of Contraceptives (Progestins). Management: Administer oral progestin-containing contraceptives at least 1-4 hours prior to or 4-6 hours after administration of a bile acid sequestrant.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May increase the serum concentration of Contraceptives (Progestins). This has been seen specifically with drospirenone. Boceprevir may increase the serum concentration of Contraceptives (Progestins). This has been seen specifically with norethindrone. Management: Patients receiving boceprevir, ribavirin, and peginterferon alfa should use two reliable forms of contraception.  Norethindrone/ethinyl estradiol may be used for one of these when norethindrone dose is at least 1 mg/day. Avoid drospirenone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosentan: May decrease the serum concentration of Contraceptives (Progestins). Management: Use an alternative (i.e., non-hormonal) means of contraception for all women of childbearing potential who are using bosentan, and do not rely on hormonal contraceptives alone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible. Management: Use of alternative, nonhormonal contraceptives is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloBAZam: May decrease the serum concentration of Contraceptives (Progestins).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: May increase the serum concentration of Contraceptives (Progestins). Management: Consider the use of an alternative, non-hormone-based contraceptive, in patients who are being treated with the elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate combination product.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Felbamate: May decrease the serum concentration of Contraceptives (Progestins). Management: Contraceptive failure is possible.  Use of an alternative, nonhormonal method of contraception is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosaprepitant: May decrease the serum concentration of Contraceptives (Progestins). The active metabolite aprepitant is likely responsible for this effect. Management: Alternative or additional methods of contraception should be used both during treatment with aprepitant or fosaprepitant and for at least one month following the last aprepitant/fosaprepitant dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible. Management: Contraceptive failure is possible.  Use of an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Griseofulvin: May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Progestogenic Properties) (eg, Bloodroot, Yucca): May enhance the adverse/toxic effect of Progestins.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     LamoTRIgine: May decrease the serum concentration of Contraceptives (Progestins). Management: Women using progestin-only &ldquo;minipill&rdquo; products may be at risk for contraceptive failure; it is unclear if other progestin-containing products would be significantly impacted.  Alternative, non-hormonal, means of contraception are recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May diminish the therapeutic effect of Contraceptives (Progestins). Mifepristone may increase the serum concentration of Contraceptives (Progestins). Management: Women of childbearing potential should use an effective, nonhormonal means of contraception during and 4 weeks following mifepristone treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: May decrease the serum concentration of Contraceptives (Progestins). Management: Use of an additional or alternative (nonhormonal) method of contraception should be considered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nevirapine: May decrease the serum concentration of Contraceptives (Progestins). Management: Instruct patients receiving nevirapine to use an alternative or additional nonhormonal contraceptive. Nevirapine product labeling however suggests that depo-medroxyprogesterone acetate may be used as a sole method of contraception.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OXcarbazepine: May decrease the serum concentration of Contraceptives (Progestins). Management: Contraceptive failure is possible.  Use of an additional or alternative, nonhormonal method of contraception is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May decrease the serum concentration of Contraceptives (Progestins). Management: Patients should use an alternative, non-hormonal based form of contraception for the duration of concurrent perampanel.  Both oral and non-oral progestin-based contraceptives are likely to be impacted by this interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible. Management: Contraceptive failure is possible.  Use of an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prucalopride: May decrease the serum concentration of Contraceptives (Progestins).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Retinoic Acid Derivatives: May diminish the therapeutic effect of Contraceptives (Progestins). Retinoic Acid Derivatives may decrease the serum concentration of Contraceptives (Progestins). Management: Two forms of effective contraception should be used in patients receiving retinoic acid derivatives.  Particularly, microdosed progesterone-only preparations may be inadequately effective.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of Contraceptives (Progestins). Contraceptive failure is possible. Management: Contraceptive failure is possible.  Use of an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inducers may decrease the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selegiline: Contraceptives (Progestins) may increase the serum concentration of Selegiline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible. Management: Consider using a product other than St John's wort.  Contraceptive failure is possible.  Use of an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May decrease the serum concentration of Contraceptives (Progestins). Management: Two different nonhormonal forms of contraception are required for women of childbearing potential taking telaprevir.  Hormonal contraceptives may be less effective during concurrent telaprevir and for up to 2 weeks after telaprevir discontinuation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: May decrease the serum concentration of Contraceptives (Progestins). Management: Caution patients that this combination may be associated with reduced contraceptive effectiveness.  Consider adding an additional (non-hormonal) contraceptive method.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tranexamic Acid: Contraceptives (Progestins) may enhance the thrombogenic effect of Tranexamic Acid.  Management: Ensure that the potential benefits of concurrent therapy outweigh the increased risk of potential thrombosis that accompanies use of tranexamic acid with hormonal contraceptives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Contraceptives (Progestins) may diminish the anticoagulant effect of Vitamin K Antagonists. In contrast, enhanced anticoagulant effects have also been noted with some products.  Management: When possible, concomitant hormonal contraceptives and coumarin derivatives should be avoided in order to eliminate the risk of thromboembolic disorders.  Consider using an alternative, nonhormonal contraceptive.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May increase the serum concentration of Contraceptives (Progestins). Contraceptives (Progestins) may increase the serum concentration of Voriconazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F192007\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Avoid ethanol (may increase risk of osteoporosis).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Bioavailability of the oral tablet is increased when taken with food; half-life is unchanged.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: St John's wort may diminish the therapeutic effect of progestin contraceptives (contraceptive failure is possible).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F191985\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F191997\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     In general, there is not an increased risk of birth defects following inadvertent use of the injectable medroxyprogesterone contraceptives early in pregnancy. There is an increased risk of minor birth defects in children whose mothers take progesterones during the first 4 months of pregnancy. Hypospadias has been reported in male babies and mild masculinization of the external genitalia has been reported in female babies exposed during the first trimester. High doses are used to impair fertility. Ectopic pregnancies have been reported with use of the MPA contraceptive injection. Median time to conception/return to ovulation following discontinuation of MPA contraceptive injection is 10 months following the last injection.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F192022\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F191998\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Composition, quality, and quantity of breast milk are not affected; adverse developmental and behavioral effects have not been noted following exposure of infant to MPA while breast-feeding. The manufacturer does not recommend the use of MPA tablets in breast-feeding mothers.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F191999\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ensure adequate calcium and vitamin D intake",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F191996\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Depo-Provera Intramuscular)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mg/mL (1 mL): $122.12",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400 mg/mL (2.5 mL): $264.23",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Depo-SubQ Provera 104 Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     104 mg/0.65 mL (0.65 mL): $142.98",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (MedroxyPROGESTERone Acetate Intramuscular)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mg/mL (1 mL): $58.23",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (MedroxyPROGESTERone Acetate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5 mg (100): $29.83",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (100): $45.01",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (100): $46.75",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Provera Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5 mg (100): $131.53",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (100): $197.74",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (100): $257.95",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F191987\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Before starting therapy, a physical exam with reference to the breasts and pelvis are recommended, including a Papanicolaou smear. Exam may be deferred if appropriate prior to administration of MPA contraceptive injection; pregnancy should be ruled out prior to use. Monitor patient closely for loss of vision; sudden onset of proptosis, diplopia, or migraine; signs and symptoms of thromboembolic disorders; signs or symptoms of depression; glucose in patients with diabetes; or blood pressure. BMD with long-term use (per manufacturer).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Adequate diagnostic measures, including endometrial sampling, if indicated, should be performed to rule out malignancy in all cases of undiagnosed abnormal vaginal bleeding.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Treatment of paraphilia/hypersexuality (Guay, 2009; Reilly, 2000): Hepatic function test (baseline and during treatment if suspected hepatotoxicity); CBC (baseline); serum testosterone (baseline then monthly for 4 months then every 6 months); serum LH and prolactin (baseline and every 6 months); FSH (baseline); glucose; bone scan (baseline then annually) if serum testosterone significantly suppressed; gallbladder function; blood pressure; weight gain",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F192000\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Climanor (GB, IE);",
"     </li>",
"     <li>",
"      Clinofem (DE);",
"     </li>",
"     <li>",
"      Condep (MY);",
"     </li>",
"     <li>",
"      Cycrin (AR, BR, NZ);",
"     </li>",
"     <li>",
"      Depo-M (TH);",
"     </li>",
"     <li>",
"      Depo-Prodasone (FR);",
"     </li>",
"     <li>",
"      Depo-Provera (AE, BH, CL, CY, EG, IL, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SG, SY, YE);",
"     </li>",
"     <li>",
"      Deporeva (PH);",
"     </li>",
"     <li>",
"      Depotrust (PH);",
"     </li>",
"     <li>",
"      Enaf-150 (TH);",
"     </li>",
"     <li>",
"      Farlutal (AE, BE, BH, BR, CL, CY, EG, FR, IQ, IR, IT, JO, KP, KW, LB, LY, NL, OM, QA, SA, SY, TR, YE);",
"     </li>",
"     <li>",
"      GestaPolar (DE);",
"     </li>",
"     <li>",
"      Gestapuran (FI, SE);",
"     </li>",
"     <li>",
"      Lyndavel (PH);",
"     </li>",
"     <li>",
"      Manodepo (TH);",
"     </li>",
"     <li>",
"      Medrone (TW);",
"     </li>",
"     <li>",
"      Medroxine (PY, UY);",
"     </li>",
"     <li>",
"      Medroxyhexal (AU);",
"     </li>",
"     <li>",
"      Megestron (MX);",
"     </li>",
"     <li>",
"      Meprate (IN);",
"     </li>",
"     <li>",
"      Meterone (TW);",
"     </li>",
"     <li>",
"      MPA Gyn 5 (DE);",
"     </li>",
"     <li>",
"      Perlutex (BB, BM, BS, BZ, DK, GY, JM, NO, SR, TT);",
"     </li>",
"     <li>",
"      Perlutex Leo (CR, DO, GT, NI, PA, SV);",
"     </li>",
"     <li>",
"      Prodafem (AT, CH);",
"     </li>",
"     <li>",
"      Progen (KP);",
"     </li>",
"     <li>",
"      Progevera (ES);",
"     </li>",
"     <li>",
"      Provera (AE, AU, BE, BF, BG, BH, BJ, CI, CL, CN, CO, CY, CZ, DK, EC, EE, EG, ET, FI, GB, GH, GM, GN, GR, HK, HN, ID, IE, IL, IN, IQ, IR, IT, JO, KE, KP, KW, LB, LR, LY, MA, ML, MR, MU, MW, MX, NE, NG, NL, NO, NZ, OM, PE, PH, PL, PT, QA, SA, SC, SD, SE, SG, SL, SN, SY, TH, TN, TW, TZ, UG, VE, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Provera LD (MY);",
"     </li>",
"     <li>",
"      Ralovera (AU);",
"     </li>",
"     <li>",
"      Ravimed (MY);",
"     </li>",
"     <li>",
"      Sayana (IL);",
"     </li>",
"     <li>",
"      Veraplex (ID, RU, TH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F191977\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits secretion of pituitary gonadotropins, which prevents follicular maturation and ovulation; causes endometrial thinning",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F191994\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Well absorbed; I.M.: Slow",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 86% to 90% primarily to albumin; does not bind to sex hormone-binding globulin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensively hepatic via hydroxylation and conjugation; forms metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Oral: 12-17 hours; I.M. (Depo-Provera&reg; Contraceptive): ~50 days; SubQ: ~40 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: Oral: 2-4 hours; I.M. (Depo-Provera&reg; Contraceptive): ~3 weeks; SubQ: ~1 week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American College of Obstetricians and Gynecologists Committee on Gynecologic Practice, ACOG Committee Opinion No. 415: \"Depot Medroxyprogesterone Acetate and Bone Effects,\"",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2008, 112(3):727-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/24/1417/abstract-text/18757687/pubmed\" id=\"18757687\" target=\"_blank\">",
"        18757687",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Anderson GL, Chlebowski RT, Aragaki AK, et al, \"Conjugated Equine Oestrogen and Breast Cancer Incidence and Mortality in Postmenopausal Women With Hysterectomy: Extended Follow-Up of the Women's Health Initiative Randomised Placebo-Controlled Trial,\"",
"      <i>",
"       Lancet Oncol,",
"      </i>",
"      2012,13(5):476-86.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/24/1417/abstract-text/22401913/pubmed\" id=\"22401913\" target=\"_blank\">",
"        22401913",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Anderson GL, Limacher M, Assaf AR, et al, \"Effects of Conjugated Equine Estrogen In Postmenopausal Women With Hysterectomy: The Women's Health Initiative Randomized Controlled Trial.\"",
"      <i>",
"       JAMA",
"      </i>",
"      , 2004, 291(14):1701-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/24/1417/abstract-text/15082697/pubmed\" id=\"15082697\" target=\"_blank\">",
"        15082697",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chlebowski RT, Kuller LH, Prentice RL, et al, \"Breast Cancer After Use of Estrogen Plus Progestin in Postmenopausal Women,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2009, 360(6):573-87.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/24/1417/abstract-text/19196674/pubmed\" id=\"19196674\" target=\"_blank\">",
"        19196674",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gagne P, &ldquo;Treatment of Sex Offenders With Medroxyprogesterone Acetate,&rdquo;",
"      <i>",
"       Am J Psychiatry",
"      </i>",
"      , 1981, 138(5):644-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/24/1417/abstract-text/6453536/pubmed\" id=\"6453536\" target=\"_blank\">",
"        6453536",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Guay DR, &ldquo;Drug Treatment of Paraphilic and Nonparaphilic Sexual Disorders,&rdquo;",
"      <i>",
"       Clin Ther",
"      </i>",
"      , 2009, 31(1):1-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/24/1417/abstract-text/19243704/pubmed\" id=\"19243704\" target=\"_blank\">",
"        19243704",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hsia J, Langer RD, Manson JE, et al, \"Conjugated Equine Estrogens and Coronary Heart Disease: The Women's Health Initiative,\"",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 2006, 166(3):357-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/24/1417/abstract-text/16476878/pubmed\" id=\"16476878\" target=\"_blank\">",
"        16476878",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      M&oslash;rch LS, L&oslash;kkegaard E, Andreasen AH, et al, &ldquo;Hormone Therapy and Ovarian Cancer,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2009, 302(3):298-305.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/24/1417/abstract-text/19602689/pubmed\" id=\"19602689\" target=\"_blank\">",
"        19602689",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Clinical Practice Guidelines in Oncology&trade;: Uterine Neoplasms,&rdquo; Version 1.2011. Available at  file://www.nccn.org/professionals/physician_gls/PDF/uterine.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      North American Menopause Society [NAMS], \"The 2012 Hormone Therapy Position Statement of The North American Menopause Society,\"",
"      <i>",
"       Menopause",
"      </i>",
"      , 2012, 19(3):257-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/24/1417/abstract-text/22367731/pubmed\" id=\"22367731\" target=\"_blank\">",
"        22367731",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Reilly DR, Delva NJ, and Hudson RW, &ldquo;Protocols for the Use of Cyproterone, Medroxyprogesterone, and Leuprolide in the Treatment of Paraphilia,&rdquo;",
"      <i>",
"       Can J Psychiatry",
"      </i>",
"      , 2000, 45(6):559-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/24/1417/abstract-text/10986575/pubmed\" id=\"10986575\" target=\"_blank\">",
"        10986575",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rossouw JE, Anderson GL, Prentice RL, et al, &ldquo;Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principle Results From the Women's Health Initiative Randomized Controlled Trial,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2002, 288(3):321-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/24/1417/abstract-text/12117397/pubmed\" id=\"12117397\" target=\"_blank\">",
"        12117397",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shumaker SA, Legault C, Rapp SR, et al, &ldquo;Estrogen Plus Progestin and the Incidence of Dementia and Mild Cognitive Impairment in Postmenopausal Women: The Women's Health Initiative Memory Study: A Randomized Controlled Trial,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(20):2651-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/24/1417/abstract-text/12771112/pubmed\" id=\"12771112\" target=\"_blank\">",
"        12771112",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sitruk-Ware R and Nath A, \"Metabolic Effects of Contraceptive Steroids,\"",
"      <i>",
"       Rev Endocr Metab Disord",
"      </i>",
"      , 2011, 12(2):63-75.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/24/1417/abstract-text/21538049/pubmed\" id=\"21538049\" target=\"_blank\">",
"        21538049",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Thibaut F, De La Barra F, Gordon H, et al, &ldquo;The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Paraphilias,&rdquo;",
"      <i>",
"       World J Biol Psychiatry",
"      </i>",
"      , 2010, 11(4):604-55.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/24/1417/abstract-text/20459370/pubmed\" id=\"20459370\" target=\"_blank\">",
"        20459370",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Thigpen JT, Brady MF, Alvarez RD, et al, &ldquo;Oral Medroxyprogesterone Acetate in the Treatment of Advanced or Recurrent Endometrial Carcinoma: A Dose-Response Study by the Gynecologic Oncology Group,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1999, 17(6):1736-44.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/24/1417/abstract-text/10561210/pubmed\" id=\"10561210\" target=\"_blank\">",
"        10561210",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9600 Version 43.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-79.123.134.1-8BED796ECD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_24_1417=[""].join("\n");
var outline_f1_24_1417=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709035\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192012\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192013\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192035\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192015\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192028\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192016\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16317858\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192017\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191989\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191974\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191992\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191991\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9348765\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192043\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192033\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191995\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191978\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192030\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191983\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192007\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191985\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191997\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192022\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191998\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191999\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191996\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191987\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192000\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191977\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191994\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9600\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9600|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?35/25/36245?source=related_link\">",
"      Medroxyprogesterone acetate: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?35/49/36631?source=related_link\">",
"      Medroxyprogesterone acetate: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_24_1418="Evaluation of the patient with neck pain and cervical spine disorders";
var content_f1_24_1418=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation of the patient with neck pain and cervical spine disorders",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/24/1418/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/24/1418/contributors\">",
"     Zacharia Isaac, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/24/1418/contributors\">",
"     Bruce C Anderson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/24/1418/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/24/1418/contributors\">",
"     Steven J Atlas, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/24/1418/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/24/1418/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/24/1418/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 22, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 10 percent of the adult population has neck pain at any one time [",
"    <a class=\"abstract\" href=\"UTD.htm?1/24/1418/abstract/1\">",
"     1",
"    </a>",
"    ]. This prevalence is similar to low back pain, but few patients with neck pain lose time from work and less than 1 percent develop neurologic deficits.",
"   </p>",
"   <p>",
"    Clinical disorders affecting the cervical spine can be categorized as those that predominantly cause neck pain and those that most often cause extremity pain",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    neurological dysfunction. Disorders that cause neck pain include cervical strain, internal disc disruption",
"    <span class=\"nowrap\">",
"     syndrome/discogenic",
"    </span>",
"    pain, cervical facet-mediated pain, cervical \"whiplash\" syndrome, and myofascial pain. Disorders that predominantly cause extremity symptoms",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    neurological dysfunction include cervical radiculopathy and cervical spondylotic myelopathy.",
"   </p>",
"   <p>",
"    The evaluation of the patient with cervical spine disease is reviewed here. The management of disorders of the neck is discussed separately (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/36/23113?source=see_link\">",
"     \"Treatment of neck pain\"",
"    </a>",
"    ). Evaluation of a patient with acute neck trauma is also discussed separately (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/34/31274?source=see_link\">",
"     \"Evaluation and acute management of cervical spinal column injuries in adults\"",
"    </a>",
"    ). Diagnosis and clinical features of cervical radiculopathy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/19/36152?source=see_link\">",
"     \"Clinical features and diagnosis of cervical radiculopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cervical spine is comprised of seven vertebrae. The articulation between the occiput and the first cervical vertebra (the atlantooccipital joint) allows for approximately one-third of flexion and extension and one-half of lateral bending of the neck [",
"    <a class=\"abstract\" href=\"UTD.htm?1/24/1418/abstract/2\">",
"     2",
"    </a>",
"    ]. The articulation between the first and second cervical vertebrae (the atlantoaxial joint) allows for 50 percent of rotational range of motion. The articulations between the second and seventh cervical vertebrae allow for approximately two-thirds of flexion and extension, 50 percent of rotation, and 50 percent of lateral bending.",
"   </p>",
"   <p>",
"    The most severe injuries and greatest wear and tear occur between C4 and C7 [",
"    <a class=\"abstract\" href=\"UTD.htm?1/24/1418/abstract/2\">",
"     2",
"    </a>",
"    ]; the nerve roots passing through the intervertebral foraminal in these areas are C5, C6, and C7. Uncovertebral articulations (also known as joints of Luschka) are present in the C3-7 spinal segments, located on the posterolateral border of the intervertebral disc, and in the anteromedial portion of the intervertebral foramen. These articulations are not true synovial joints, but can hypertrophy, associated with disc degeneration, and result in narrowing of the intervertebral foramen. This foraminal narrowing is a common cause of cervical radiculopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/24/1418/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The cervical and trapezius muscles have two major functions: to support and provide movement and alignment for the head and neck and to protect the spinal cord and spinal nerves when the spinal column is under mechanical stress. The normal cervical spine has a shallow lordosis, maintained by the neck muscles.",
"   </p>",
"   <p>",
"    This lordosis can be decreased in patients with degenerative changes. Severe degenerative changes in the cervical spine can result in reversal of the lordosis. The lordosis may also become accentuated in compensation for patients with prominent thoracic kyphosis. Alterations in spinal alignment, however, have not definitively been demonstrated to cause cervical pain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Neuroanatomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are eight cervical spinal nerves. Each spinal nerve arises from the spinal cord by two roots, the ventral and dorsal spinal roots. The ventral root contains motor efferent fibers from alpha motor neurons in the ventral horn of the spinal cord. The dorsal root carries primary sensory afferent fibers from cells in the dorsal root ganglion. The dorsal and ventral spinal roots combine to form the spinal nerve.",
"   </p>",
"   <p>",
"    This spinal nerve then divides into two branches, a dorsal primary ramus and a ventral primary ramus. The dorsal ramus divides and supplies innervation to muscular, cutaneous, and articular branches for posterior neck structures. The ventral rami supply the prevertebral and paravertebral muscles and form the brachial plexus, which subsequently innervates the upper limb. The sensory cervical dermatomes are illustrated in the figure (",
"    <a class=\"graphic graphic_figure graphicRef53006 \" href=\"UTD.htm?21/8/21634\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A myotome is the group of muscles innervated by a spinal nerve. The diaphragm is innervated by C3 to C5 spinal nerves and respiratory paralysis may result from spinal cord injuries above C5.",
"   </p>",
"   <p>",
"    Cervical radiculopathy may be caused by degenerative changes in the spine that impact the ventral root and cause focal weakness. Specific findings with different levels of nerve root involvement are discussed below. (See",
"    <a class=\"local\" href=\"#H29\">",
"     'Cervical level correlates to findings'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 2007 task force on neck pain, representing multiple specialties and institutions, recommends a classification system for neck pain severe enough to cause patients to seek care [",
"    <a class=\"abstract\" href=\"UTD.htm?1/24/1418/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Grade I: No signs of major pathology and little interference with daily activities",
"     </li>",
"     <li>",
"      Grade II: No signs of major pathology but may impact daily activities",
"     </li>",
"     <li>",
"      Grade III: Neck pain with neurological signs or symptoms (radiculopathy)",
"     </li>",
"     <li>",
"      Grade IV: Neck pain with major pathology (eg, fracture, myelopathy, neoplasm, spinal infection)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These classifications can be helpful in determining urgency of care and appropriateness of intervention. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/36/23113?source=see_link\">",
"     \"Treatment of neck pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     FACTORS SUGGESTING SIGNIFICANT DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although cervical spine degenerative changes are the most common cause of acute and chronic neck pain, it is important to be mindful of signs and symptoms that may indicate more serious pathology warranting additional diagnostic and therapeutic steps (",
"    <a class=\"graphic graphic_table graphicRef70313 \" href=\"UTD.htm?2/20/2379\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The following symptoms in patients presenting with neck pain suggest the potential for significant disease:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Neck pain associated with headache, shoulder or hip girdle pain, or visual symptoms in an older person may suggest rheumatologic disease (eg, polymyalgia rheumatica or giant cell arteritis). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/32/13832?source=see_link\">",
"       \"Clinical manifestations and diagnosis of polymyalgia rheumatica\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/33/18969?source=see_link\">",
"       \"Clinical manifestations of giant cell (temporal) arteritis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Neck pain with a history of fever, chills, unexplained weight loss, immunosuppression, cancer, or intravenous drug use should raise suspicion for tumor or infection.",
"     </li>",
"     <li>",
"      Neck pain with neurological signs or symptoms (arm clumsiness, gait difficulty, bowel or bladder dysfunction, Babinki's sign) may suggest cervical myelopathy. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Extremity pain and/or neurologic deficit'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      A shock-like paresthesia occurring with neck flexion (Lhermitte's phenomenon) suggests compression of the cervical cord by a midline disc herniation or spondylosis but may also be a sign of intramedullary pathology such as a multiple sclerosis plaque. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/19/36152?source=see_link\">",
"       \"Clinical features and diagnosis of cervical radiculopathy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/44/5832?source=see_link\">",
"       \"Anatomy and localization of spinal cord disorders\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Anterior neck pain is not a typical presentation of spondylosis-related referral patterns and non spinal causes of neck pain should be considered.",
"     </li>",
"     <li>",
"      Patients with a recent history of major fall or trauma should be immobilized, stabilized, and transported by ambulance to an emergency department. A discussion of evaluation of the trauma patient is presented separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/34/31274?source=see_link\">",
"       \"Evaluation and acute management of cervical spinal column injuries in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1003404623\">",
"    <span class=\"h1\">",
"     FACTORS SUGGESTING PERSISTENT SYMPTOMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Predictive factors for persistent neck pain symptoms include greater age, accompanying low back pain, neck trauma, headache, radiation of pain, being employed, and prior episodes of neck pain [",
"    <a class=\"abstract\" href=\"UTD.htm?1/24/1418/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     AXIAL NECK PAIN SYNDROMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neck pain can arise from a variety of causes [",
"    <a class=\"abstract\" href=\"UTD.htm?1/24/1418/abstract/6\">",
"     6",
"    </a>",
"    ]. Systemic diseases, such as rheumatoid arthritis, spondyloarthritis, polymyalgia rheumatica, or bone metastases should be considered in appropriate patients. Degenerative changes are the most common etiology for axial neck pain. An approach to diagnosis is described below, for patients in whom there is no evidence of rheumatologic, oncologic, and infectious etiologies on history and examination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Cervical strain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cervical strain is a nonspecific diagnosis, classically used to describe an injury to the cervical paraspinal muscles and ligaments with associated spasm of the cervical and upper back muscles. The diagnosis of cervical strain is reasonable in patients with acute axial neck and trapezius pain, where neurological dysfunction has been excluded.",
"   </p>",
"   <p>",
"    Cervical strain may result from the physical stresses of everyday life, including poor posture and sleeping habits. Typically, symptoms are experienced as pain, stiffness, and tightness in the upper back or shoulder, and last for up to six weeks. Patients with chronic symptoms that extend beyond the expected time frame for resolution should not receive this nonspecific diagnosis; muscle pain alone should not be routinely considered a chronic nociceptor.",
"   </p>",
"   <p>",
"    Potential mechanisms for chronic pain include cervical discogenic pain, facet mediated pain, cervical spondylotic myelopathy, cervical radicular pain, myofascial pain, and centrally- or peripherally-mediated neuropathic pain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Cervical spondylosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term cervical spondylosis is variably used to include soft tissue, disc, and degenerative bony lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?1/24/1418/abstract/7\">",
"     7",
"    </a>",
"    ]. Degenerative changes in the cervical spine are apparent on radiographs of many adults over the age of 30 [",
"    <a class=\"abstract\" href=\"UTD.htm?1/24/1418/abstract/8\">",
"     8",
"    </a>",
"    ]. The abnormalities include a sequential change in the intervertebral discs, with osteophyte formation along the vertebral bodies, and changes in the facet joints and laminal arches. There is a continuum from normal aging to the overtly pathologic state. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/19/36152?source=see_link&amp;anchor=H6#H6\">",
"     \"Clinical features and diagnosis of cervical radiculopathy\", section on 'Pathophysiology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/18/27944?source=see_link\">",
"     \"Cervical spondylotic myelopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Correlation between the degree of radiographic change and the presence or severity of pain is poor [",
"    <a class=\"abstract\" href=\"UTD.htm?1/24/1418/abstract/8\">",
"     8",
"    </a>",
"    ]. Given the prevalence of radiographic abnormalities in asymptomatic subjects, clear distinction of the clinical entity of cervical spondylosis is difficult [",
"    <a class=\"abstract\" href=\"UTD.htm?1/24/1418/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Cervical discogenic pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cervical degenerative disc disease is more aptly a radiologic diagnosis, rather than a clinical syndrome, as it is commonly seen on x-ray studies in both symptomatic and asymptomatic patients. In one twelve-year prospective longitudinal study, changes on MRI indicating progressive disc degeneration were seen in 81 percent of 223 subjects who were asymptomatic (mean age 39 years) at study onset [",
"    <a class=\"abstract\" href=\"UTD.htm?1/24/1418/abstract/9\">",
"     9",
"    </a>",
"    ]. For this reason, other terms have been introduced to describe patients who are symptomatic with disc-related neck pain: cervical internal disc disruption syndrome or cervical discogenic pain [",
"    <a class=\"abstract\" href=\"UTD.htm?1/24/1418/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Cervical discogenic pain may be the most common cause of neck pain.",
"   </p>",
"   <p>",
"    In contrast to patients with cervical disc herniations, cervical discogenic pain refers to derangement in the architecture of the disc that results in mechanical neck pain with or without features of inflammation. The degenerative process that occurs in the intervertebral disc is associated with an inability to effectively distribute pressures between the disc, vertebral endplates, and facet joints.",
"   </p>",
"   <p>",
"    Axial pain is more severe than extremity pain in cervical discogenic pain. Extremity pain can occur, but is felt to result from somatic referral rather than spinal nerve root impingement. Symptoms are often exacerbated when the neck is held in one position for prolonged periods, such as occurs with driving, reading, or working at a computer. There is often associated muscle tightness and spasms.",
"   </p>",
"   <p>",
"    Examination should demonstrate axial neck discomfort with range of motion, a decreased range of motion, and a benign neurological examination. MRI imaging demonstrating the degree of degeneration does not accurately implicate which discs are symptomatically painful; asymptomatic degenerative changes are common [",
"    <a class=\"abstract\" href=\"UTD.htm?1/24/1418/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Cervical facet syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The zygapophyseal joint, commonly referred to as the facet joint, can cause axial pain and is probably the most common cause of whiplash-related neck pain and headaches [",
"    <a class=\"abstract\" href=\"UTD.htm?1/24/1418/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Historically, patients often have a history of trauma with an abrupt flexion-extension type injury, or an occupation which leads to repeatedly positioning the neck in extension.",
"   </p>",
"   <p>",
"    Pain is often midline or offset slightly to one side. Symptoms can be somatically referred to the shoulders, periscapular region, occiput, or proximal limb. As with cervical discogenic pain, axial symptoms are greater than extremity symptoms.",
"   </p>",
"   <p>",
"    Unfortunately, there is no specific historical examination, or imaging finding, that provides confirmatory diagnostic information. A fluoroscopically guided intraarticular injection of a small aliquot of local anesthetic, or anesthetization of the innervation of the joint resulting in relief are considered the definitive diagnostic tests.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Whiplash injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cervical \"whiplash\" syndrome is caused by a traumatic event with an abrupt",
"    <span class=\"nowrap\">",
"     flexion/extension",
"    </span>",
"    movement to the cervical spine. Symptoms of whiplash include severe pain, spasm, loss of range of motion in the neck, and occipital headache. Pain can be persistent with little identifiable abnormality seen on MRI, CT, x-ray, or bone scan imaging. Often multiple structures can be injured including soft tissues, spinal nerve, intervertebral disc, posterior longitudinal ligament, interspinous ligaments, alar ligaments, facet joints, or other osseous structures.",
"   </p>",
"   <p>",
"    The injury is common but remains poorly understood [",
"    <a class=\"abstract\" href=\"UTD.htm?1/24/1418/abstract/16\">",
"     16",
"    </a>",
"    ]. In a case controlled study of 1843 drivers involved in a motor vehicle accident, 26 percent of whom had neck pain for more than one day, eight variables were identified as risk factors for whiplash injury: female, younger age, prior history of neck pain, rear collision, stationary vehicle, severity of collision, not being at fault, and monotonous work [",
"    <a class=\"abstract\" href=\"UTD.htm?1/24/1418/abstract/17\">",
"     17",
"    </a>",
"    ]. In a systematic review of 47 studies, approximately 50 percent of adults with whiplash injury reported neck pain symptoms at one year [",
"    <a class=\"abstract\" href=\"UTD.htm?1/24/1418/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathology of the condition is unclear. Microvascular bleeding and local release of inflammatory mediators may explain the acute symptoms, but some patients remain symptomatic for many months or even years. Soft tissue injury may be associated with the degree of impairment. A study using high resolution MRI imaging of the C spine in patients with a remote history of whiplash injury (mean 6 years), and symptoms that had persisted at least 3 months following injury, demonstrated soft tissue damage, particularly of the alar ligaments, not seen in MRI images in control patients [",
"    <a class=\"abstract\" href=\"UTD.htm?1/24/1418/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a study in the United Kingdom (UK), the most important predictors of pain at one year were pain severity at the time of the rear-end collision and the presence of a compensation claim [",
"    <a class=\"abstract\" href=\"UTD.htm?1/24/1418/abstract/20\">",
"     20",
"    </a>",
"    ]. In addition to pain symptoms, neck mobility is another important risk factor that predicts disability one year after whiplash injury [",
"    <a class=\"abstract\" href=\"UTD.htm?1/24/1418/abstract/21\">",
"     21",
"    </a>",
"    ]. Chronic whiplash symptoms may also be associated with different cultural expectations; 50 percent of Canadian and British subjects surveyed anticipated chronic neck pain following a hypothetical whiplash injury compared to negligible numbers from respondents in Lithuania and Germany, where late neck pain prevalence is very low [",
"    <a class=\"abstract\" href=\"UTD.htm?1/24/1418/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. A legislative change in Australia, removing financial compensation for pain and suffering from whiplash injuries, was associated with improvement in functional status and pain indices in patients with whiplash, compared to historical controls [",
"    <a class=\"abstract\" href=\"UTD.htm?1/24/1418/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Cervical myofascial pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regional pain with associated trigger points, taut bands, and pressure sensitivity has been called myofascial pain. Myofascial pain can be a nonspecific manifestation of any pathologic condition that causes pain from the neck to the shoulder and should not be considered a defining diagnosis. Myofascial pain can also be associated with muscle sensitivity, depression, anxiety, insomnia, and likely represents a less generalized variant of fibromyalgia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Diffuse skeletal hyperostosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diffuse skeletal hyperostosis (DISH) is a syndrome of inappropriate bone deposition in the insertions of the ligaments and tendons. Large osteophytes connect adjacent vertebral bodies in a somewhat asymmetric fashion. The diagnosis is based on three criteria for spinal radiographs [",
"    <a class=\"abstract\" href=\"UTD.htm?1/24/1418/abstract/25\">",
"     25",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The presence of calcification or ossification along the anterolateral aspects of at least four contiguous vertebral levels.",
"     </li>",
"     <li>",
"      Relative preservation of intervertebral disc height in the involved vertebral segments without extensive changes of primary degenerative disc disease.",
"     </li>",
"     <li>",
"      The absence of apophyseal joint ankylosis or sacroiliac joint erosions, sclerosis, or intraarticular bony ankylosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    DISH can be associated with stiffness, loss of mobility, and pain, but can also often be asymptomatic. The bony fusion that results from the hyperostosis may cause mechanical pain at segments adjacent to the fused segments. Prominent anterior vertebral hyperostosis associated with DISH can cause dysphagia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/59/43960?source=see_link\">",
"     \"Diffuse idiopathic skeletal hyperostosis (DISH)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     EXTREMITY PAIN AND/OR NEUROLOGIC DEFICIT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Cervical spondylotic myelopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cervical spondylotic myelopathy is defined by degenerative changes narrowing the spinal canal, resulting in cervical spinal cord injury or dysfunction. Patients may present with a variety of neurological complaints: weakness, coordination impairment, gait disturbance, bowel or bladder retention or incontinence, and sexual dysfunction. The differential diagnosis for cervical spondylotic myelopathy includes multiple sclerosis, syringomyelia, tumor, epidural abscess, and amyotrophic lateral sclerosis. Distinguishing cervical spondylotic myelopathy from other causes of neck pain is critical because optimal neurological recovery depends on early surgical decompression.",
"   </p>",
"   <p>",
"    Diagnosis, clinical features, and management of cervical spondylotic myelopathy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/18/27944?source=see_link\">",
"     \"Cervical spondylotic myelopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Cervical radiculopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cervical radiculopathy refers to dysfunction of the spinal nerve root that may manifest with pain, weakness, reflex changes, or sensory changes. Multiple conditions can give rise to cervical radiculopathy, including cervical foraminal stenosis, cervical herniated disc, herpes zoster, Lyme radiculopathy, or diabetic polyradiculopathy, but degenerative changes in the spine are overwhelmingly more common than the other causes, accounting for 70 to 90 percent of cases.",
"   </p>",
"   <p>",
"    Diagnosis and clinical features of cervical radiculopathy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/19/36152?source=see_link\">",
"     \"Clinical features and diagnosis of cervical radiculopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     NON-SPINAL CAUSES OF NECK PAIN",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Thoracic outlet syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The thoracic outlet syndrome can present as neck and shoulder pain with referred pain to the upper extremities and variable neurovascular signs and symptoms. The triad of numbness, weakness, and a sensation of swelling of the upper limbs is strongly suggestive of thoracic outlet syndrome. Examination may demonstrate a positive Roos sign (repetitive and vigorous hand grip while the arms are abducted overhead) or a positive Adson's test (diminution of the radial pulse when the arm is abducted, extended backward, the head is turned ipsilaterally, and the patient inspires). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/53/2906?source=see_link&amp;anchor=H24#H24\">",
"     \"Brachial plexus syndromes\", section on 'Thoracic outlet syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Herpes zoster",
"    </span>",
"    &nbsp;&mdash;&nbsp;Herpes zoster (shingles) may present with unilateral radicular symptoms without neurologic findings. The rash may not appear for several days after the onset of pain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/8/23688?source=see_link\">",
"     \"Epidemiology and pathogenesis of varicella-zoster virus infection: Herpes zoster\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Diabetic neuropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diabetes mellitus can be associated with various neuropathic pain syndromes related to vasculitis of the vasa vasorum. Cervical and thoracic polyradiculopathy, plexopathy, and peripheral entrapments can be associated with neck, thoracic, scapular, extremity pain",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    weakness. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/7/18551?source=see_link\">",
"     \"Clinical manifestations and diagnosis of diabetic polyneuropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Other causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of neck pain is broad. Although the majority of neck pain complaints are related to musculoskeletal causes, numerous other conditions can present with a constellation of symptoms that include neck pain. While the differential listed below should be kept in mind in evaluating the patient with neck pain, diagnosis of these conditions is usually evident from accompanying symptoms (ie, fever, neck stiffness, diffuse joint pain, etc.):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Malignancy &mdash; tumors involving the cervical spinal column",
"     </li>",
"     <li>",
"      Vascular &mdash; vertebral artery or carotid artery dissection",
"     </li>",
"     <li>",
"      Cardiovascular &mdash; angina and myocardial infarction (causing neck, chest, and arm symptoms that may mimic cervical radicular pain)",
"     </li>",
"     <li>",
"      Infection &mdash; pharyngeal abscess, meningitis, subdiaphragmatic abscess, herpes zoster, Lyme disease",
"     </li>",
"     <li>",
"      Visceral &mdash; esophageal obstruction, biliary disease, apical lung tumor",
"     </li>",
"     <li>",
"      Referred shoulder pain &mdash; impingement, adhesive capsulitis, rotator cuff tear",
"     </li>",
"     <li>",
"      Rheumatologic &mdash; polymyalgia rheumatica, fibromyalgia",
"     </li>",
"     <li>",
"      Neurologic &mdash; cervical dystonia, tension headache, Chiari malformations",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     PHYSICAL EXAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to the patient who has suffered serious head or neck trauma differs dramatically from the typical office evaluation of neck complaints. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/34/31274?source=see_link\">",
"     \"Evaluation and acute management of cervical spinal column injuries in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Routine cervical spine evaluation includes the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Observe movement and resting posture of the head and neck",
"     </li>",
"     <li>",
"      Estimate cervical range of motion",
"     </li>",
"     <li>",
"      Palpate the paraspinal and upper trapezial muscles",
"     </li>",
"     <li>",
"      Evaluate for radicular neurological symptoms: reflexes, motor and sensory testing",
"     </li>",
"     <li>",
"      Evaluate for upper motor neuron signs",
"     </li>",
"     <li>",
"      Perform provocative maneuvers for radicular pain",
"     </li>",
"     <li>",
"      Examine the shoulder for painful range of motion",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     General observation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The routine examination begins by noting the movement of the head and neck. Posture and general movements (rigid and guarded, general stiffness, or loose and free) should be consistent during the interview phase as well as during the actual examination. Lack of consistency may be the only clue to malingering in the case of trauma- related whiplash and cervical radiculopathy that are under litigation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Range of motion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neck rotation and lateral bending, when combined with palpation of the trapezius and paraspinal muscles for tenderness and spasm, are used to assess the degree of cervical spine involvement. The presence of torticollis can be consistent with acute muscle spasm or a herniated disk. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/60/970?source=see_link\">",
"     \"Classification and evaluation of dystonia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Assessment of the shoulder is important since overlapping symptoms can occur.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The cervical spine can rotate an average of 90 degrees (",
"      <a class=\"graphic graphic_picture graphicRef64373 \" href=\"UTD.htm?9/18/9508\">",
"       picture 1",
"      </a>",
"      ). Less rotation is abnormal.",
"     </li>",
"     <li>",
"      The cervical spine can bend an average of 45 degrees laterally (",
"      <a class=\"graphic graphic_picture graphicRef61374 \" href=\"UTD.htm?8/13/8403\">",
"       picture 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The cervical spine can forward flex to 60 degrees.",
"     </li>",
"     <li>",
"      The cervical spine can extend backward 75 degrees.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Abnormal neck range of motion suggests an injury to the cervical spine but does not indicate a specific diagnostic etiology. Conditions such as cervical strain, pain inhibited movement, cervical discogenic pain, cervical facet syndrome, DISH, cervical radiculopathy, and cervical myeloradiculopathy can all be associated with range of motion alterations. Neck rotation may be more prominently affected by upper cervical spine abnormalities (C1 to C3) whereas lateral flexion impairment may be more prominent with lower cervical spine disease (C4 to C7).",
"   </p>",
"   <p>",
"    Range of motion of the cervical spine appears to be an important predictor of outcome in patients with whiplash injury. In one prospective study of 141 patients with acute whiplash, reduction in cervical range of motion was the single best predictor of long-term handicap, with a sensitivity and specificity of 73 and 91 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?1/24/1418/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Muscle palpation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Local muscular tenderness can result from trauma (a direct blow to the upper back or trauma to the head), or can be a nonspecific feature of a number of cervical spine syndromes. The upper trapezius and paraspinal muscles should be palpated to determine the degree of tenderness and spasm (",
"    <a class=\"graphic graphic_picture graphicRef66174 \" href=\"UTD.htm?36/4/36929\">",
"     picture 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Trapezius muscle tenderness is a nonspecific finding seen in many conditions and is consistent with a diagnosis of cervical muscle strain, fibromyalgia, whiplash, or cervical radiculopathy. Severe muscular rigidity and guarding are associated with severe neck strain, occult vertebral body fracture, and",
"    <span class=\"nowrap\">",
"     fracture/dislocation.",
"    </span>",
"    Muscle spasm is so dramatic with neck fracture that the neck is totally rigid.",
"   </p>",
"   <p>",
"    The superior division of the trapezius muscle is often quite hard to palpation in the elderly. The dorsal kyphotic posture (prominent C7 spinous process, drooped shoulders, and head forward) places the trapezius under constant tension. The extremes of rotation may show endpoint stiffness and mild pain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Neurologic examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;A detailed upper extremity neurologic examination is warranted for patients with radicular symptoms. The neurological exam should involve the following components: muscle strength, reflex testing, muscle tone, gait, and testing for upper motor neuron signs. A detailed neurological examination is described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38377?source=see_link\">",
"     \"The detailed neurologic examination in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A negative neurological examination indicates a low likelihood of root compression; positive findings, however, are not specific for root compression [",
"    <a class=\"abstract\" href=\"UTD.htm?1/24/1418/abstract/4\">",
"     4",
"    </a>",
"    ]. These correlations, however, are tempered by variability in the quality of the neurological examination performed.",
"   </p>",
"   <p>",
"    The majority of patients with pure sensory radiculopathy have a good prognosis and respond to a combination of rest, exercise, and occasionally medication or corticosteroid injection. In contrast, patients with sensorimotor involvement (with or without spinal cord compression) have a less predictable prognosis; they are more likely to have more dramatic degrees of disk herniation, are at higher risk for nerve damage, and are more likely to require surgical intervention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Muscle strength",
"    </span>",
"    &nbsp;&mdash;&nbsp;Strength should be evaluated by testing the following actions against resistance: shoulder abduction, elbow flexion and extension, wrist flexion and extension, and lower limb extension and flexion. Strength should be recorded using the Medical Research Council manual muscle testing scale as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      0 = No contraction",
"     </li>",
"     <li>",
"      1 = Visible muscle twitch but no movement of the joint",
"     </li>",
"     <li>",
"      2 = Weak contraction insufficient to overcome gravity",
"     </li>",
"     <li>",
"      3 = Weak contraction able to overcome gravity but no additional resistance",
"     </li>",
"     <li>",
"      4 = Weak contraction able to overcome some resistance but not full resistance",
"     </li>",
"     <li>",
"      5 = Normal; able to overcome full resistance",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Reflex testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Deep tendon reflexed should be checked at the bicep, brachioradialis, and tricep muscles and compared from side to side. Grading scale is as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      0 = No observable reflex",
"     </li>",
"     <li>",
"      1 = Trace reflex",
"     </li>",
"     <li>",
"      2 = Normal reflex",
"     </li>",
"     <li>",
"      3 = Very brisk reflex",
"     </li>",
"     <li>",
"      4 = Clonus",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Cervical level correlates to findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is some overlap in clinical symptoms and physical findings that suggest involvement of a specific nerve root. In general, however, assessment of strength, reflexes, and sensory examination, in combination with patient symptoms, can target a specific root lesion (",
"    <a class=\"graphic graphic_table graphicRef74632 \" href=\"UTD.htm?0/56/908\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      C4 radiculopathy may affect the levator scapular and trapezius muscles, resulting in weakness in shoulder elevation. There is no reliable associated reflex.",
"     </li>",
"     <li>",
"      C5 radiculopathy is associated with weakness of the rhomboid, deltoid, bicep, and infraspinatus muscles. Patients may have weakness of shoulder abduction and external rotation. The bicep reflex may be diminished.",
"     </li>",
"     <li>",
"      C5-C6 paracentral",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      foraminal herniation or foraminal stenosis at C5-C6 affects the C6 nerve root and produces pain at the shoulder tip and trapezius with radiation to the anterior upper arm, radial forearm, and thumb, and sensory impairment in these areas. C6 radiculopathy can easily be confused for C5 or C7 radiculopathy. Weakness can overlap with the C5 or C7 muscles. Muscles affected include: infraspinatus, bicep, brachioradialis, pronator teres, and tricep. Weakness involves flexion at the elbow, or shoulder external rotation. The bicep or brachioradialis reflex may be diminished.",
"     </li>",
"     <li>",
"      C6-C7 paracentral",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      foraminal herniation or foraminal stenosis at C6-C7 affects the C7 nerve root and produces pain at the shoulder blade, pectoral area, and medial axilla with radiation to posterolateral upper arm, dorsal elbow and forearm, index and medial digits or all of the fingers, and sensory impairment in these areas. C7 radiculopathy can result in weakness of the tricep, pronator teres, flexor carpi radialis. Weakness involves the elbow extensors, and forearm pronators. There may be a diminished tricep reflex.",
"     </li>",
"     <li>",
"      C7-T1 paracentral",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      foraminal herniation or foraminal stenosis at C7-T1 causes C8 radiculopathy. Weakness can be present in the opponens pollicis, flexor digitorum profundus, flexor pollicis longus, and hand intrinsic muscles. Clinically, patients present with symptoms similar to an ulnar or median motor neuropathy and can have weakness of finger abductors and grip strength; they may also have findings suggesting median motor neuropathy. No reliable reflex test is available.",
"     </li>",
"     <li>",
"      Central disc herniation at any cervical level &mdash; Large central disc herniation or any cause of spinal cord compression in the midline can produce a cervical myelopathy with bilateral upper motor neuron signs in the extremities. Small central herniations are common and are often not clinically associated with radicular pain or myelopathic features.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Provocative maneuvers",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Spurling's maneuver &mdash; The Spurling's and modified Spurling's maneuver can reproduce the patient's radicular pain (",
"      <a class=\"graphic graphic_picture graphicRef57386 \" href=\"UTD.htm?41/39/42609\">",
"       picture 4",
"      </a>",
"      ). The Spurling's maneuver (also called the neck compression test) is performed by keeping the head in a forward flexed, ipsilaterally rotated, and ipsilaterally tilted position. The modified Spurling's maneuver is performed by keeping the head extended, ipsilaterally rotated, and ipsilaterally tilted. Additional axial load by applying pressure on top of the head can be applied. Reproduction of symptoms beyond the shoulder is considered positive. Reproduction of neck pain alone is nonspecific.",
"      <br/>",
"      <br/>",
"      This maneuver is highly specific for the presence of cervical root compression, but the sensitivity is low [",
"      <a class=\"abstract\" href=\"UTD.htm?1/24/1418/abstract/27\">",
"       27",
"      </a>",
"      ]. One study, as an example, using electrodiagnostic testing as a reference, found a sensitivity of 30 percent and specificity of 93 percent for the Spurling's maneuver [",
"      <a class=\"abstract\" href=\"UTD.htm?1/24/1418/abstract/28\">",
"       28",
"      </a>",
"      ]. Thus, a positive test is helpful, but a negative test does not rule out radicular pain.",
"      <br/>",
"      <br/>",
"      The Spurling maneuver should be performed with caution in patients with suspected rheumatoid arthritis, cervical malformations, or metastatic disease since it may cause further injury to the spine in these patients.",
"     </li>",
"     <li>",
"      Upper limb tension test &mdash; The Elvey's upper limb tension sign is a root tension sign for the upper extremity, akin to the straight leg raise in the lower extremity. The head is turned contralaterally, the arm is abducted with the elbow extended. Reproduction of arm symptoms is considered positive. The sensitivity and specificity of Elvey's upper limb tension test were 0.97 and 0.22 in one study [",
"      <a class=\"abstract\" href=\"UTD.htm?1/24/1418/abstract/29\">",
"       29",
"      </a>",
"      ]. This test is most useful for ruling out radiculopathy.",
"     </li>",
"     <li>",
"      Manual neck distraction test &mdash; Vertical upward traction is applied simultaneously under the jaw and at the occiput, mimicking the effect of traction. This test is positive if the pain is decreased when the head is lifted, indicating pressure on the nerve roots has been relieved (",
"      <a class=\"graphic graphic_picture graphicRef56871 \" href=\"UTD.htm?2/23/2417\">",
"       picture 5",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A combination of tests may provide the most accurate diagnostic assessment. One study analyzed a cluster of four tests: Spurling's maneuver, Elvey's upper limb tension test, cervical rotation less than 60 degrees, and diminution in neck symptoms with the manual neck distraction test [",
"    <a class=\"abstract\" href=\"UTD.htm?1/24/1418/abstract/30\">",
"     30",
"    </a>",
"    ]. The post-test probability for radiculopathy in patients with two, three, or four positive tests was 21, 65, and 90 percent, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     CONFIRMATORY TESTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plain radiographs, MRI or CT scans,",
"    <span class=\"nowrap\">",
"     electromyography/nerve",
"    </span>",
"    conduction studies",
"    <span class=\"nowrap\">",
"     (EMG/NCS),",
"    </span>",
"    and blood tests are useful for determining diagnosis in selected patients with cervical spine disorders.",
"   </p>",
"   <p>",
"    Because degenerative changes can occur at multiple levels, neurologic findings must be correlated with radiographic abnormalities. As an example, symptoms and signs involving C6 should correlate with the presence of foraminal encroachment at the C5-C6 intervertebral space.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Radiography",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H964210303\">",
"    <span class=\"h3\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with nontraumatic neck pain, radiographic imaging (plain films, MRI, or CT scan) is indicated in the following circumstances [",
"    <a class=\"abstract\" href=\"UTD.htm?1/24/1418/abstract/31\">",
"     31",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Age &gt;50 years with new symptoms",
"     </li>",
"     <li>",
"      Constitutional symptoms (fevers, chills, unexplained weight loss)",
"     </li>",
"     <li>",
"      Moderate to severe neck pain lasting more than six weeks",
"     </li>",
"     <li>",
"      Progressive neurological findings",
"     </li>",
"     <li>",
"      Infectious risk (eg, injection drug use, immunosuppression)",
"     </li>",
"     <li>",
"      History of malignancy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Indications for imaging studies in patients who have experienced neck trauma are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/34/31274?source=see_link&amp;anchor=H14#H14\">",
"     \"Evaluation and acute management of cervical spinal column injuries in adults\", section on 'Clinical decision rules for obtaining radiographs'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/34/31274?source=see_link&amp;anchor=H15#H15\">",
"     \"Evaluation and acute management of cervical spinal column injuries in adults\", section on 'Plain x-rays versus CT'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H964210387\">",
"    <span class=\"h3\">",
"     Plain films",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plain films are indicated in patients with nontraumatic neck complaints who are greater than 50 years with new symptoms.",
"   </p>",
"   <p>",
"    The routine cervical series of x-rays consists of seven views, including the odontoid (open-mouth), lateral, PA, two oblique views, lateral view in flexion, and lateral view in extension. However, in a series of 258 patients undergoing radiography for evaluation of neck-related disorders (axial cervical, upper extremity radicular, or myelopathic symptoms), flexion and extension views did not lead to findings that changed clinical management [",
"    <a class=\"abstract\" href=\"UTD.htm?1/24/1418/abstract/32\">",
"     32",
"    </a>",
"    ]. The additional expense and radiation exposure associated with dynamic views are not routinely warranted. Thus, the cervical series should include five views: odontoid, lateral, PA, and both oblique views [",
"    <a class=\"abstract\" href=\"UTD.htm?1/24/1418/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The lateral view demonstrates vertebral alignment; the normal cervical lordotic curve can be replaced by a straightened or even a reversed curve in moderate to severe cases of cervical strain. The lateral view is also used to screen for the degree of osteoarthritis (at the facet and paravertebral joints), disk space narrowing (osteoarthritis or radiculopathy), or bony pathology (compression fracture) (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef55348 \" href=\"UTD.htm?39/3/39999\">",
"     image 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Oblique views are primarily used to determine the role of foraminal encroachment (osteophytes reducing the overall diameter of the neuroforamena) (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef78738 \" href=\"UTD.htm?42/2/43055\">",
"     image 2",
"    </a>",
"    ). However, radiographic presence of foraminal stenosis can both underestimate and overestimate the degree of foraminal stenosis because of the variable angle of the cervical foramenae.",
"   </p>",
"   <p>",
"    Severe torticollis may cause a lateral deviation of the cervical spine that is best appreciated on a PA view of the neck. Odontoid views are most appropriate in patients with acute trauma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h3\">",
"     MRI or CT scan",
"    </span>",
"    &nbsp;&mdash;&nbsp;MRI and CT scans are more sensitive than plain films for identifying some serious conditions, including disc herniations, spinal cord compression, infection, and malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/24/1418/abstract/33-35\">",
"     33-35",
"    </a>",
"    ]. MRI should be the first-line imaging study performed in patients with progressive signs or symptoms of neurologic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?1/24/1418/abstract/31\">",
"     31",
"    </a>",
"    ]. MRI should also be obtained if there is a suspicion for infection or malignancy. Some experts also believe that MRI is indicated for patients who have moderate to severe neck symptoms beyond six weeks, even if plain films are negative, although this is not a criterion in the American College of Radiology guidelines. &nbsp;",
"   </p>",
"   <p>",
"    In the absence of risk factors for serious disease, MRI imaging is not necessary in patients with mild neck pain. Mild pain could be defined as self-described pain that is &ldquo;mild&rdquo; or other equivalent (a low numerical value on a pain rating scale less than",
"    <span class=\"nowrap\">",
"     3/10),",
"    </span>",
"    does not limit or interrupt daily activities (such as driving, desk work, or sleep), does not affect occupation, and is easily ignorable when distracted. Other reassuring features include waxing and waning severity over months and years, a reasonable response to mild analgesics and heat, &ldquo;gelling&rdquo; phenomenon (stiffness after prolonged single position), and an increase in symptoms with weather changes. Patients with moderate or severe chronic neck pain should undergo further imaging with MRI even in the absence of neurological compromise when symptoms affect sleep, occupation, basic daily activities, or if the patient requires injection or surgical treatments. If there is a contraindication to MRI, CT is indicated.",
"   </p>",
"   <p>",
"    Patients with dramatic bony tenderness combined with dramatic guarding of cervical movement should have imaging to evaluate for a possible occult fracture. CT scans show better definition of the fracture line than MRI, and can be obtained quickly in such patients who often have a difficult time lying still due to pain. In patients with acute whiplash injury, MRI findings showed limited evidence of specific changes compared to asymptomatic controls, suggesting little role for MRI in patients with this injury [",
"    <a class=\"abstract\" href=\"UTD.htm?1/24/1418/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    MRI or CT also is indicated if referral for interventional procedures or surgery is being considered. Whether the patient is being sent to the spine surgeon, pain specialist, or physiatrist, further anatomic detail as outlined by the MRI along with clinical correlation define the most likely level for intervention. The choice of test varies with the clinical features of the patient.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      MRI detects soft tissue processes including disc herniations, foraminal stenosis, central stenosis, and tumor. MRI can also detect spinal cord changes from myelopathy, fractures, and infection. A non-contrast MRI is sufficient in the majority of cases. The addition of gadolinium contrast intravenously allows better diagnosis of infection, tumor, or post surgical epidural fibrosis [",
"      <a class=\"abstract\" href=\"UTD.htm?1/24/1418/abstract/37-40\">",
"       37-40",
"      </a>",
"      ], and can be ordered subsequently if the noncontrast study is inconclusive.",
"     </li>",
"     <li>",
"      CT scan can detect degenerative changes such as disc herniations, foraminal stenosis, central stenosis, facet osteoarthritis, tumor, and fractures. CT is a better study than MRI when facet osteoarthritis or other osseous changes are suspected. There is significant radiation exposure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Administration of gadolinium-containing MRI contrast agents should be avoided in patients with moderately or severely impaired renal function (eg, estimated glomerular filtration rate &lt; 15-30",
"    <span class=\"nowrap\">",
"     mL/min).",
"    </span>",
"    If gadolinium-based imaging must be performed in a patient with moderate to severely impaired renal function, there may be a role for dialysis to reduce the risk of development of nephrogenic systemic fibrosis (NSF). Approaches to prevention of this disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/22/31082?source=see_link&amp;anchor=H24#H24\">",
"     \"Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure\", section on 'If gadolinium must be given'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    MRI does not expose the patient to radiation, but exposes the patient to a strong magnetic field, which precludes patients with pacemakers, older intracranial vascular clips, and prior eye injury with metal fragments. Most metal placed as part of orthopedic procedures, including spine procedures, is considered permissible.",
"   </p>",
"   <p>",
"    A limitation of MRI is that anatomic abnormalities such as disk protrusion or extrusion are present in up to 30 percent of asymptomatic individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?1/24/1418/abstract/8,12\">",
"     8,12",
"    </a>",
"    ]. In one study of 100 patients referred for MRI of the larynx who had no neck symptoms, cervical disc protrusion or herniation was seen in 20 percent of patients between the ages of 45 and 54, and 57 percent of those older than age 64 [",
"    <a class=\"abstract\" href=\"UTD.htm?1/24/1418/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Other studies",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h3\">",
"     Electrodiagnostic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;EMG should be considered when peripheral nerve entrapment syndromes are a potential cause for extremity symptoms that can mimic cervical radicular pain. EMGs should be considered when there is more prominent pain and dysesthesia in the extremities than in the neck. In some patients, the pain symptoms travel retrograde to the neck. EMG studies are not indicated in patients without suspected radiculopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/24/1418/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The needle portion of the",
"    <span class=\"nowrap\">",
"     EMG/NCS",
"    </span>",
"    is the most useful test to identify cervical radiculopathy but will only identify radiculopathy and its associated radicular pain when motor axonal injury is present. It is important to recognize that cervical radicular pain can exist in the absence of axonal injury. Irritation of the dorsal root ganglion and the dorsal sensory afferent fibers can result in pain without motor injury.",
"   </p>",
"   <p>",
"    The sensitivity of the needle EMG increases with the number of muscles sampled. One study demonstrated that sampling six upper limb muscles along with the paraspinal muscles was sufficient to identify cervical radiculopathy by EMG [",
"    <a class=\"abstract\" href=\"UTD.htm?1/24/1418/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h3\">",
"     Blood tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blood studies are not routinely indicated, but should be ordered, based on individual patient history and examination, when non-spinal causes of neck pain (ie, rheumatologic, infectious, or oncologic) are suspected. Serologic markers of inflammation such as erythrocyte sedimentation rate and c-reactive protein should be normal in degenerative causes of neck pain such as cervical radiculopathy, stenosis, myelopathy, discogenic pain, and facet syndrome. However, the erythrocyte sedimentation rate and c-reactive protein may be elevated in patients with polymyalgia rheumatica, rheumatoid arthritis, or infectious processes such as septic discitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/32/13832?source=see_link\">",
"     \"Clinical manifestations and diagnosis of polymyalgia rheumatica\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h1\">",
"     EVALUATION OF THE TRAUMA PATIENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with significant head and neck trauma should be immobilized, stabilized, and transported by ambulance to an emergency department. A discussion of evaluation of the trauma patient is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/34/31274?source=see_link\">",
"     \"Evaluation and acute management of cervical spinal column injuries in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?22/31/23026?source=see_link\">",
"       \"Patient information: Neck pain (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?16/45/17106?source=see_link\">",
"       \"Patient information: Whiplash (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?26/35/27188?source=see_link\">",
"       \"Patient information: Neck pain (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Disorders of the cervical spine can cause either neck pain or extremity pain with or without neurological dysfunction. The most severe injuries and wear and tear occur between C4 and C7, affecting the C5, 6, and 7 nerve roots. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Anatomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are several types of neck pain syndromes, including cervical strain, cervical spondylosis, cervical discogenic pain, whiplash injury, cervical myofascial pain, and diffuse skeletal hyperostosis. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Axial neck pain syndromes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although cervical spine degenerative changes are the most common cause of neck pain, it is important to be aware of signs and symptoms that may indicate more serious pathology (",
"      <a class=\"graphic graphic_table graphicRef70313 \" href=\"UTD.htm?2/20/2379\">",
"       table 1",
"      </a>",
"      ): history of trauma or cancer, unexplained weight loss,",
"      <span class=\"nowrap\">",
"       fever/chills,",
"      </span>",
"      immunosuppression, intravenous drug use, chronic steroid use, and neurologic signs or symptoms. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Factors suggesting significant disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The physical examination should include observation of neck movement, range of motion, palpation of the trapezius and paraspinal muscles, neurologic examination for radicular and upper motor neuron signs, and provocative maneuvers (see",
"      <a class=\"local\" href=\"#H22\">",
"       'Physical examination'",
"      </a>",
"      above). In patients with nontraumatic neck pain, radiographic imaging is indicated in the following circumstances (see",
"      <a class=\"local\" href=\"#H964210303\">",
"       'Indications'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Age &gt;50 years with new symptoms",
"     </li>",
"     <li>",
"      Constitutional symptoms (fevers, chills, unexplained weight loss)",
"     </li>",
"     <li>",
"      Moderate to severe neck pain lasting more than six weeks",
"     </li>",
"     <li>",
"      Progressive neurologic findings",
"     </li>",
"     <li>",
"      Infectious risk (eg, injection drug use, immunosuppression)",
"     </li>",
"     <li>",
"      History of malignancy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the absence of risk factors for serious disease, plain films are indicated in all patients with nontraumatic neck pain who are age &gt;50 years and have new symptoms. (See",
"      <a class=\"local\" href=\"#H964210387\">",
"       'Plain films'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Magnetic resonance imaging (MRI) should be the first-line imaging study performed in patients with progressive signs or symptoms of neurologic disease. MRI should also be obtained if there is a suspicion for infection or malignancy and if there are moderate to severe neck symptoms beyond six weeks, even if plain films are negative. (See",
"      <a class=\"local\" href=\"#H34\">",
"       'MRI or CT scan'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Electromyography (EMG) testing can distinguish between peripheral nerve entrapment syndromes and cervical radiculopathy and should be considered when pain and dysesthesia is more prominent in the extremities than in the neck. Blood laboratory testing for patients with neck symptoms is not routinely indicated. (See",
"      <a class=\"local\" href=\"#H35\">",
"       'Other studies'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/24/1418/abstract/1\">",
"      Hadler NM. Illness in the workplace: the challenge of musculoskeletal symptoms. J Hand Surg Am 1985; 10:451.",
"     </a>",
"    </li>",
"    <li>",
"     Monahan JJ, Waite RJ. Cervical spine. In: Orthopaedics in primary care, Steinberg GG, Akins CM, Baran DT (Eds), Lippincott Williams Wilkins, Baltimore 1999.",
"    </li>",
"    <li>",
"     Anderson BC. Office Orthopedics for Primary Care: Diagnosis and Treatment, 3rd ed, WB Saunders Company, Philadelphia 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/24/1418/abstract/4\">",
"      Guzman J, Haldeman S, Carroll LJ, et al. Clinical practice implications of the Bone and Joint Decade 2000-2010 Task Force on Neck Pain and Its Associated Disorders: from concepts and findings to recommendations. Spine (Phila Pa 1976) 2008; 33:S199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/24/1418/abstract/5\">",
"      Schellingerhout JM, Heymans MW, Verhagen AP, et al. Prognosis of patients with nonspecific neck pain: development and external validation of a prediction rule for persistence of complaints. Spine (Phila Pa 1976) 2010; 35:E827.",
"     </a>",
"    </li>",
"    <li>",
"     Binder AL. Cervical pain syndromes. In: Oxford Textbook of Rheumatology, Maddison PJ (Ed), Oxford Medical Publications, Oxford 1993. p.1060.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/24/1418/abstract/7\">",
"      Resnick D. Degenerative diseases of the vertebral column. Radiology 1985; 156:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/24/1418/abstract/8\">",
"      Teresi LM, Lufkin RB, Reicher MA, et al. Asymptomatic degenerative disk disease and spondylosis of the cervical spine: MR imaging. Radiology 1987; 164:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/24/1418/abstract/9\">",
"      Okada E, Matsumoto M, Ichihara D, et al. Aging of the cervical spine in healthy volunteers: a 10-year longitudinal magnetic resonance imaging study. Spine (Phila Pa 1976) 2009; 34:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/24/1418/abstract/10\">",
"      Grubb SA, Kelly CK. Cervical discography: clinical implications from 12 years of experience. Spine (Phila Pa 1976) 2000; 25:1382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/24/1418/abstract/11\">",
"      Slipman CW, Plastaras C, Patel R, et al. Provocative cervical discography symptom mapping. Spine J 2005; 5:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/24/1418/abstract/12\">",
"      Boden SD, McCowin PR, Davis DO, et al. Abnormal magnetic-resonance scans of the cervical spine in asymptomatic subjects. A prospective investigation. J Bone Joint Surg Am 1990; 72:1178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/24/1418/abstract/13\">",
"      Schellhas KP, Smith MD, Gundry CR, Pollei SR. Cervical discogenic pain. Prospective correlation of magnetic resonance imaging and discography in asymptomatic subjects and pain sufferers. Spine (Phila Pa 1976) 1996; 21:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/24/1418/abstract/14\">",
"      Bogduk N, Marsland A. On the concept of third occipital headache. J Neurol Neurosurg Psychiatry 1986; 49:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/24/1418/abstract/15\">",
"      Lord SM, Barnsley L, Wallis BJ, Bogduk N. Chronic cervical zygapophysial joint pain after whiplash. A placebo-controlled prevalence study. Spine (Phila Pa 1976) 1996; 21:1737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/24/1418/abstract/16\">",
"      Kasch H, Bach FW, Stengaard-Pedersen K, Jensen TS. Development in pain and neurologic complaints after whiplash: a 1-year prospective study. Neurology 2003; 60:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/24/1418/abstract/17\">",
"      Wiles NJ, Jones GT, Silman AJ, Macfarlane GJ. Onset of neck pain after a motor vehicle accident: a case-control study. J Rheumatol 2005; 32:1576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/24/1418/abstract/18\">",
"      Carroll LJ, Holm LW, Hogg-Johnson S, et al. Course and prognostic factors for neck pain in whiplash-associated disorders (WAD): results of the Bone and Joint Decade 2000-2010 Task Force on Neck Pain and Its Associated Disorders. Spine (Phila Pa 1976) 2008; 33:S83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/24/1418/abstract/19\">",
"      Krakenes J, Kaale BR. Magnetic resonance imaging assessment of craniovertebral ligaments and membranes after whiplash trauma. Spine (Phila Pa 1976) 2006; 31:2820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/24/1418/abstract/20\">",
"      Pobereskin LH. Whiplash following rear end collisions: a prospective cohort study. J Neurol Neurosurg Psychiatry 2005; 76:1146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/24/1418/abstract/21\">",
"      Kasch H, Qerama E, Kongsted A, et al. The risk assessment score in acute whiplash injury predicts outcome and reflects biopsychosocial factors. Spine (Phila Pa 1976) 2011; 36:S263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/24/1418/abstract/22\">",
"      Ferrari R, Lang C. A cross-cultural comparison between Canada and Germany of symptom expectation for whiplash injury. J Spinal Disord Tech 2005; 18:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/24/1418/abstract/23\">",
"      Ferrari R, Obelieniene D, Russell A, et al. Laypersons' expectation of the sequelae of whiplash injury. A cross-cultural comparative study between Canada and Lithuania. Med Sci Monit 2002; 8:CR728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/24/1418/abstract/24\">",
"      Cameron ID, Rebbeck T, Sindhusake D, et al. Legislative change is associated with improved health status in people with whiplash. Spine (Phila Pa 1976) 2008; 33:250.",
"     </a>",
"    </li>",
"    <li>",
"     Resnick D, Berthiaume MJ, Sartoris D. Textbook of Rheumatology, 4th ed, Kelley WN, Harris ED, Ruddy S, Sledge CB (Eds), WB Saunders, Philadelphia 1993.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/24/1418/abstract/26\">",
"      Kasch H, Bach FW, Jensen TS. Handicap after acute whiplash injury: a 1-year prospective study of risk factors. Neurology 2001; 56:1637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/24/1418/abstract/27\">",
"      Viikari-Juntura E, Porras M, Laasonen EM. Validity of clinical tests in the diagnosis of root compression in cervical disc disease. Spine (Phila Pa 1976) 1989; 14:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/24/1418/abstract/28\">",
"      Tong HC, Haig AJ, Yamakawa K. The Spurling test and cervical radiculopathy. Spine (Phila Pa 1976) 2002; 27:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/24/1418/abstract/29\">",
"      Wainner RS, Fritz JM, Irrgang JJ, et al. Reliability and diagnostic accuracy of the clinical examination and patient self-report measures for cervical radiculopathy. Spine (Phila Pa 1976) 2003; 28:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/24/1418/abstract/30\">",
"      Rubinstein SM, Pool JJ, van Tulder MW, et al. A systematic review of the diagnostic accuracy of provocative tests of the neck for diagnosing cervical radiculopathy. Eur Spine J 2007; 16:307.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.acr.org/SecondaryMainMenuCategories/quality_safety/app_criteria/pdf/ExpertPanelonMusculoskeletalImaging/ChronicNeckPainDoc9.aspx (Accessed on January 24, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/24/1418/abstract/32\">",
"      White AP, Biswas D, Smart LR, et al. Utility of flexion-extension radiographs in evaluating the degenerative cervical spine. Spine (Phila Pa 1976) 2007; 32:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/24/1418/abstract/33\">",
"      Boutin RD, Steinbach LS, Finnesey K. MR imaging of degenerative diseases in the cervical spine. Magn Reson Imaging Clin N Am 2000; 8:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/24/1418/abstract/34\">",
"      Chen CJ, Hsu HL, Niu CC, et al. Cervical degenerative disease at flexion-extension MR imaging: prediction criteria. Radiology 2003; 227:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/24/1418/abstract/35\">",
"      Nordin M, Carragee EJ, Hogg-Johnson S, et al. Assessment of neck pain and its associated disorders: results of the Bone and Joint Decade 2000-2010 Task Force on Neck Pain and Its Associated Disorders. Spine (Phila Pa 1976) 2008; 33:S101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/24/1418/abstract/36\">",
"      Anderson SE, Boesch C, Zimmermann H, et al. Are there cervical spine findings at MR imaging that are specific to acute symptomatic whiplash injury? A prospective controlled study with four experienced blinded readers. Radiology 2012; 262:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/24/1418/abstract/37\">",
"      Bundschuh CV, Modic MT, Ross JS, et al. Epidural fibrosis and recurrent disk herniation in the lumbar spine: MR imaging assessment. AJR Am J Roentgenol 1988; 150:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/24/1418/abstract/38\">",
"      Frocrain L, Duvauferrier R, Husson JL, et al. Recurrent postoperative sciatica: evaluation with MR imaging and enhanced CT. Radiology 1989; 170:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/24/1418/abstract/39\">",
"      Ross JS, Masaryk TJ, Schrader M, et al. MR imaging of the postoperative lumbar spine: assessment with gadopentetate dimeglumine. AJR Am J Roentgenol 1990; 155:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/24/1418/abstract/40\">",
"      Colletti PM, Dang HT, Deseran MW, et al. Spinal MR imaging in suspected metastases: correlation with skeletal scintigraphy. Magn Reson Imaging 1991; 9:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/24/1418/abstract/41\">",
"      Dillingham TR, Lauder TD, Andary M, et al. Identification of cervical radiculopathies: optimizing the electromyographic screen. Am J Phys Med Rehabil 2001; 80:84.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7773 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-6FA69E1D15-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_24_1418=[""].join("\n");
var outline_f1_24_1418=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H40\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Neuroanatomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      FACTORS SUGGESTING SIGNIFICANT DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1003404623\">",
"      FACTORS SUGGESTING PERSISTENT SYMPTOMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      AXIAL NECK PAIN SYNDROMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Cervical strain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Cervical spondylosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Cervical discogenic pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Cervical facet syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Whiplash injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Cervical myofascial pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Diffuse skeletal hyperostosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      EXTREMITY PAIN AND/OR NEUROLOGIC DEFICIT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Cervical spondylotic myelopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Cervical radiculopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      NON-SPINAL CAUSES OF NECK PAIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Thoracic outlet syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Herpes zoster",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Diabetic neuropathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Other causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      PHYSICAL EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      General observation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Range of motion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Muscle palpation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Neurologic examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Muscle strength",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Reflex testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Cervical level correlates to findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Provocative maneuvers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      CONFIRMATORY TESTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Radiography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H964210303\">",
"      - Indications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H964210387\">",
"      - Plain films",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      - MRI or CT scan",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Other studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      - Electrodiagnostic testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      - Blood tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      EVALUATION OF THE TRAUMA PATIENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/7773\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/7773|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?39/3/39999\" title=\"diagnostic image 1\">",
"      Cervical osteoarthritis xray",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?42/2/43055\" title=\"diagnostic image 2\">",
"      Foraminal encroachment xray",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/7773|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/8/21634\" title=\"figure 1\">",
"      Cervical dermatomes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/7773|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/18/9508\" title=\"picture 1\">",
"      Passive neck rotation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/13/8403\" title=\"picture 2\">",
"      Lateral bending of the neck",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/4/36929\" title=\"picture 3\">",
"      Trapezius muscle palpation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/39/42609\" title=\"picture 4\">",
"      Spurling maneuver",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/23/2417\" title=\"picture 5\">",
"      Manual neck distraction test",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/7773|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/20/2379\" title=\"table 1\">",
"      Symptoms serious disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/56/908\" title=\"table 2\">",
"      Symptoms of cervical root lesions",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/44/5832?source=related_link\">",
"      Anatomy and localization of spinal cord disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/53/2906?source=related_link\">",
"      Brachial plexus syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/18/27944?source=related_link\">",
"      Cervical spondylotic myelopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/60/970?source=related_link\">",
"      Classification and evaluation of dystonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/19/36152?source=related_link\">",
"      Clinical features and diagnosis of cervical radiculopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/7/18551?source=related_link\">",
"      Clinical manifestations and diagnosis of diabetic polyneuropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/32/13832?source=related_link\">",
"      Clinical manifestations and diagnosis of polymyalgia rheumatica",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/33/18969?source=related_link\">",
"      Clinical manifestations of giant cell (temporal) arteritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/59/43960?source=related_link\">",
"      Diffuse idiopathic skeletal hyperostosis (DISH)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/8/23688?source=related_link\">",
"      Epidemiology and pathogenesis of varicella-zoster virus infection: Herpes zoster",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/34/31274?source=related_link\">",
"      Evaluation and acute management of cervical spinal column injuries in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/22/31082?source=related_link\">",
"      Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?26/35/27188?source=related_link\">",
"      Patient information: Neck pain (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/31/23026?source=related_link\">",
"      Patient information: Neck pain (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/45/17106?source=related_link\">",
"      Patient information: Whiplash (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38377?source=related_link\">",
"      The detailed neurologic examination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/36/23113?source=related_link\">",
"      Treatment of neck pain",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_24_1419="Treatment for mild pediatric lead poisoning - level 5 to 14";
var content_f1_24_1419=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F70588&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F70588&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Treatment strategies for patients with venous lead level 5 mcg/dL (0.24 micromol/L) to 14 mcg/dL (0.68 micromol/L)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        1.",
"       </td>",
"       <td>",
"        Report to appropriate health authorities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2.",
"       </td>",
"       <td>",
"        Repeat lead level in one month, then every&nbsp;three to four&nbsp;months until &lt;5 mcg/dL (0.24 micromol/L)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3.",
"       </td>",
"       <td>",
"        Provide parents with educational and nutritional counseling",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_24_1419=[""].join("\n");
var outline_f1_24_1419=null;
var title_f1_24_1420="Examination of the septic appearing infant";
var content_f1_24_1420=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F63744&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F63744&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Linking physical examination and diagnosis in the septic-appearing infant",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Physical findings",
"       </td>",
"       <td class=\"subtitle1\">",
"        Likely diagnosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bulging fontanelle, fever",
"       </td>",
"       <td>",
"        Meningitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bulging fontanelle, no fever",
"       </td>",
"       <td>",
"        Hydrocephalus as with inflicted head injury",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Skin vesicles",
"       </td>",
"       <td>",
"        Herpes simplex virus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Temperature &gt;39&deg;C, female or an uncircumcised male",
"       </td>",
"       <td>",
"        UTI",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Weak cry, hypotonia, hyporeflexic, diminished or absent gag reflex, ptosis, mydriasis, weak suck, opthalmoparesis",
"       </td>",
"       <td>",
"        Infant botulism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pyloric tumor (\"olive\") in the right upper quadrant",
"       </td>",
"       <td>",
"        Pyloric stenosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Scrotum exam with tender swelling at the external ring, above and lateral to the pubis without an upper limit",
"       </td>",
"       <td>",
"        Incarcerated hernia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Apnea, bradycardia, temperature instability, bloody stools, abdominal distention",
"       </td>",
"       <td>",
"        Necrotizing enterocolitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Murmur, gallop, hepatosplenomegaly, edema, rales, grunting, flaring, retracting",
"       </td>",
"       <td>",
"        Congenital heart disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ambiguous genitalia in females, virilization in males",
"       </td>",
"       <td>",
"        Congenital adrenal hyperplasia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Jaundice, opisthotonus, high-pitched cry",
"       </td>",
"       <td>",
"        Acute bilirubin encephalopathy",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     UTI: urinary tract infection.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_24_1420=[""].join("\n");
var outline_f1_24_1420=null;
var title_f1_24_1421="Malignancies highrisk TLS";
var content_f1_24_1421=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F59645&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F59645&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Malignancies commonly diagnosed in patients perceived to be at high risk for developing tumor lysis syndrome",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\" rowspan=\"2\">",
"       Malignancy",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"2\">",
"       <p>",
"        Pediatric",
"       </p>",
"       <p>",
"        (n = 682)",
"       </p>",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"2\">",
"       <p>",
"        Adult",
"       </p>",
"       <p>",
"        (n = 387)",
"       </p>",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"2\">",
"       <p>",
"        Total",
"       </p>",
"       <p>",
"        (n = 1069)",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2\">",
"       Number",
"      </td>",
"      <td class=\"subtitle2\">",
"       Percent",
"      </td>",
"      <td class=\"subtitle2\">",
"       Number",
"      </td>",
"      <td class=\"subtitle2\">",
"       Percent",
"      </td>",
"      <td class=\"subtitle2\">",
"       Number",
"      </td>",
"      <td class=\"subtitle2\">",
"       Percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Acute lymphoblastic leukemia",
"      </td>",
"      <td>",
"       433",
"      </td>",
"      <td>",
"       63",
"      </td>",
"      <td>",
"       73",
"      </td>",
"      <td>",
"       19",
"      </td>",
"      <td>",
"       506",
"      </td>",
"      <td>",
"       47",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Acute myeloid leukemia",
"      </td>",
"      <td>",
"       74",
"      </td>",
"      <td>",
"       11",
"      </td>",
"      <td>",
"       104",
"      </td>",
"      <td>",
"       27",
"      </td>",
"      <td>",
"       178",
"      </td>",
"      <td>",
"       17",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Chronic lymphocytic leukemia",
"      </td>",
"      <td>",
"       0",
"      </td>",
"      <td>",
"       0",
"      </td>",
"      <td>",
"       37",
"      </td>",
"      <td>",
"       10",
"      </td>",
"      <td>",
"       37",
"      </td>",
"      <td>",
"       3.5",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Chronic myeloid leukemia",
"      </td>",
"      <td>",
"       6",
"      </td>",
"      <td>",
"       0.9",
"      </td>",
"      <td>",
"       36",
"      </td>",
"      <td>",
"       9",
"      </td>",
"      <td>",
"       42",
"      </td>",
"      <td>",
"       4",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Non-Hodgkin's lymphoma",
"      </td>",
"      <td>",
"       122",
"      </td>",
"      <td>",
"       18",
"      </td>",
"      <td>",
"       109",
"      </td>",
"      <td>",
"       28",
"      </td>",
"      <td>",
"       231",
"      </td>",
"      <td>",
"       22",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hodgkin's disease",
"      </td>",
"      <td>",
"       8",
"      </td>",
"      <td>",
"       1.2",
"      </td>",
"      <td>",
"       6",
"      </td>",
"      <td>",
"       1.6",
"      </td>",
"      <td>",
"       14",
"      </td>",
"      <td>",
"       1.3",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Multiple myeloma",
"      </td>",
"      <td>",
"       0",
"      </td>",
"      <td>",
"       0",
"      </td>",
"      <td>",
"       15",
"      </td>",
"      <td>",
"       3.9",
"      </td>",
"      <td>",
"       15",
"      </td>",
"      <td>",
"       1.4",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Other hematologic malignancies",
"      </td>",
"      <td>",
"       5",
"      </td>",
"      <td>",
"       0.7",
"      </td>",
"      <td>",
"       3",
"      </td>",
"      <td>",
"       0.7",
"      </td>",
"      <td>",
"       8",
"      </td>",
"      <td>",
"       0.7",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Solid tumors",
"      </td>",
"      <td>",
"       34",
"      </td>",
"      <td>",
"       5",
"      </td>",
"      <td>",
"       4",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       38",
"      </td>",
"      <td>",
"       3.6",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    NOTE: Data represent consecutive patients enrolled onto a compassionate-use trial evaluating the efficacy and safety of rasburicase in patients with cancer who presented with, or were at risk of developing, hyperuricemia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Coiffier B, Altman A, Pui CH, et al. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol 2008; 26:2767. Copyright &copy;2008 American Society of Clinical Oncology. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_24_1421=[""].join("\n");
var outline_f1_24_1421=null;
var title_f1_24_1422="Dose response curves in HTN";
var content_f1_24_1422=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F52852&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F52852&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Dose relation between therapeutic effect and toxicity with antihypertensive drugs",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 364px; height: 250px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The theoretical therapeutic and toxic effect curves of antihypertensive agents vary based upon the administered dose. The theoretical effects of a single drug given at two different doses (10 and 20 units) are shown. At a dose of 10 units, the antihypertensive agent has a minimal toxic effect (A') and a moderate therapeutic effect (A). Doubling the dose, however, is associated with substantial toxic effects (B') but little increase in therapeutic efficacy (B).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Epstein, M, Bakris, G, Arch Intern Med 1996; 156:1969.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_24_1422=[""].join("\n");
var outline_f1_24_1422=null;
var title_f1_24_1423="Pincer mechanism";
var content_f1_24_1423=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F67314&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F67314&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pincer mechanism",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 325px; height: 200px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The pincer mechanism is one mechanism of injury that is proposed to explain the pathogenesis of cervical cord neurapraxia. It is hypothesized that during extension the cervical cord becomes compressed between the posterior margin of one vertebral body and the anterior margin of the spinous process of the vertebra below it. Such compression is most likely to occur in a hyperextension injury with axial loading.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_24_1423=[""].join("\n");
var outline_f1_24_1423=null;
